var title_f8_50_8992="Waters view facial bones";
var content_f8_50_8992=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F79369&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F79369&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Water's view of facial bones",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Zygomaticomaxillary complex fracture on the left. Water's view shows soft tissue swelling over the entire face. However, there is asymmetry between the bony structures. Notice the fractures of the floor of the orbit (open arrow), lateral maxillary wall (long arrow), and lateral wall of the orbit (arrowhead) on the left.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wolters Kluwer. Copyright &copy; 2008.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_50_8992=[""].join("\n");
var outline_f8_50_8992=null;
var title_f8_50_8993="Imidapril: International drug information";
var content_f8_50_8993=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Imidapril: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4304134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Novarok (JP);",
"     </li>",
"     <li>",
"      Tanatril (AT, DE, FR, GB, IT, JP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F1979037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Imidapril Hydrochloride",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1979039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Angiotensin-Converting Enzyme (ACE) Inhibitor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1979042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1979038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: Initial: 2.5-5 mg/day before food; if necessary increase dose at intervals of at least 3 weeks; usual maintenance dose: 10 mg once daily; maximum: 20 mg/day (elderly, 10 mg/day)",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1979041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 5 mg, 10 mg, 20 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10394 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.102.30.19-24B6C7082C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_50_8993=[""].join("\n");
var outline_f8_50_8993=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4304134\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979037\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979039\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979042\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979038\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821238\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979041\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10394\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10394|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_50_8994="Microscopy pilot wheel";
var content_f8_50_8994=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F74383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F74383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The pilot's wheel of paracoccidioidomycosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 356px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Paracoccidioidomycosis. The lung contains P. brasiliensis, which displays a mother cell surrounded by multiple budding yeasts.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rubin, E, MD and Farber, JL, MD. Pathology, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 1999. Copyright &copy;1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_50_8994=[""].join("\n");
var outline_f8_50_8994=null;
var title_f8_50_8995="Wolff-Parkinson-White syndrome";
var content_f8_50_8995=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Wolff-Parkinson-White syndrome (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?8/50/8995/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/50/8995/contributors\" id=\"au6340\">",
"       Bradley P Knight, MD, FACC",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?8/50/8995/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/50/8995/contributors\" id=\"se214\">",
"       Samuel L&eacute;vy, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?8/50/8995/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/50/8995/contributors\" id=\"de7537\">",
"       Brian C Downey, MD, FACC",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?8/50/8995?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Wolff-Parkinson-White (WPW) syndrome is a condition in which episodes of fast heart rate (called tachycardia) occur because of an abnormal extra electrical pathway in the heart. People with WPW may experience palpitations, dizziness, lightheadedness, and fainting, although some people with WPW have no symptoms. Treatments are available for those who do experience symptoms. The long-term outcome of people with WPW is excellent, especially when treatments are used to eliminate the abnormal conduction pathway.",
"    </p>",
"    <p>",
"     This topic review discusses how the heart functions in people with WPW, the signs and symptoms of the condition, how it is diagnosed, and the available treatments.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      THE HEART",
"     </span>",
"    </p>",
"    <p>",
"     A brief review of the structure of the heart and the normal electrical conduction system will aid in the understanding of WPW. The heart is made up of four chambers: the right atrium, right ventricle, left atrium, and left ventricle (",
"     <a class=\"graphic graphic_figure graphicRef77576 \" href=\"UTD.htm?11/14/11495\">",
"      figure 1",
"     </a>",
"     ). Blood returning to the heart from the body flows into the right atrium, and then into the right ventricle. Blood is pumped out of the right ventricle into the lungs (where red blood cells fill with oxygen) and then returns to the heart in the left atrium. Blood in the left atrium flows into the left ventricle, which pumps the blood to the rest of the body through the aorta, the major artery.",
"    </p>",
"    <p>",
"     Heart muscle cells are stimulated by electrical impulses that cause them to contract in a uniform way at a regular rate (",
"     <a class=\"graphic graphic_figure graphicRef71235 \" href=\"UTD.htm?4/20/4420\">",
"      figure 2",
"     </a>",
"     ). This contraction produces the heartbeat, which causes blood to be pumped out of the heart into arteries and then to all parts of the body. The flow of blood into arteries can be measured by feeling the pulse, which corresponds to the heartbeat.",
"    </p>",
"    <p>",
"     In order to bring the electrical impulse to all parts of the heart in a uniform fashion, the heart has a series of electrical pathways, known as the conduction system. A normal heartbeat is produced when the heart's natural pacemaker, the sinoatrial (or sinus) node, which is an area of specialized cells in the upper part of the right atrium, sends out a series of regular electrical impulses. These impulses travel in an organized way along conduction tissue in the heart, passing first across both atria, then to an area between the atria and the ventricles known as the atrioventricular node (AV node), and finally spreading across the ventricles, which are the heart's main pumping chambers. The normal heart rate is generally around 60 to 100 beats per minute.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      CAUSES OF WOLFF-PARKINSON-WHITE SYNDROME",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Conduction in WPW",
"     </span>",
"     &nbsp;&mdash;&nbsp;In the normal heart, the atria are electrically isolated as they are separated by fibrous atrioventricular rings. Patients with WPW syndrome have an extra electrical pathway between the atria and the ventricles, known as an accessory pathway. This abnormal pathway directly connects the atria and ventricles and bypasses the AV node, which is the slowest conducting part of the heart's electrical system (",
"     <a class=\"graphic graphic_figure graphicRef53316 \" href=\"UTD.htm?41/32/42500\">",
"      figure 3",
"     </a>",
"     ). As a result, the normal sinus impulse can travel down the normal pathway through the AV node, as well as the more rapidly conducting accessory pathway. This allows the impulse traveling through the accessory pathway to reach the ventricle earlier, causing what is termed \"preexcitation.\"",
"    </p>",
"    <p>",
"     The presence of two pathways (the normal one and the accessory one) between the atria and ventricles poses a risk of developing a \"short circuit\" of the normal electrical pathway, which can result in an abnormally fast heart rate (tachycardia). Patients who have recurring tachycardias because of this abnormal pathway are said to have the WPW syndrome. Some patients have the WPW pathway, but no tachycardia. They do not have WPW syndrome, but may develop it at some point. These patients are said to have a WPW pattern, which can be detected on a routine electrocardiogram (ECG).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Causes of tachycardia",
"     </span>",
"     &nbsp;&mdash;&nbsp;The presence of an accessory pathway alone does not explain tachycardia, since the sinus node rate generally ranges from 60 to 100 beats per minute. There are two mechanisms of tachycardia in the WPW syndrome:",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h3\">",
"      Atrial fibrillation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some patients have an abnormal rhythm called atrial fibrillation. In atrial fibrillation, the atria are beating in an uncoordinated manner at a rate of 350 to 600 beats per minute. The AV node normally blocks most of these impulses so that the ventricular rate (which is felt with the pulse) is usually less than 170 beats per minute. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/16/261?source=see_link\">",
"      \"Patient information: Atrial fibrillation (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     With WPW, conduction is much more rapid and frequent, and more impulses get to the ventricles by crossing the accessory pathway. The ventricles may beat at a rate of 200 or more beats per minute, and there is a risk that the heart can beat up to 300 times per minute. Even higher rates of up to 300 beats per minute can occur with atrial flutter, another type of abnormal atrial rhythm.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Atrioventricular reentrant tachycardia",
"     </span>",
"     &nbsp;&mdash;&nbsp;The second mechanism is called atrioventricular reentrant tachycardia (AVRT). In this tachycardia, an electrical impulse travels down one pathway (either through the AV node or the accessory pathway) and then back up the other, creating a repeating loop. This circular or \"reentrant\" electrical activity sends impulses to the ventricles at an abnormally high rate, causing the heart to beat from 140 to 250 times per minute.",
"    </p>",
"    <p>",
"     The tachycardia of WPW syndrome begins suddenly and may stop just as suddenly on its own. Sometimes, however, treatment is necessary to end the tachycardia and reinstate a normal rhythm. Patients with WPW syndrome typically have recurrent episodes of the tachycardia.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      WOLFF-PARKINSON-WHITE SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     As mentioned earlier, patients can have the WPW pathway (WPW pattern) but never experience tachycardia or any other symptoms. If symptoms do occur (WPW syndrome), they are related to the development of an irregular heart rhythm and a rapid heart rate.",
"    </p>",
"    <p>",
"     During tachycardia, patients may experience palpitations, dizziness, lightheadedness, fainting, or rarely, sudden death. Sudden death is usually a result of the very rapid ventricular response seen in WPW syndrome as well as atrial fibrillation or atrial flutter. At a very rapid heart rate the ventricles cannot pump blood effectively to other vital organs. Fortunately, the incidence of sudden death in people with WPW is quite low, ranging from 0 to 0.39 percent per year, with risk lowest among those with WPW pattern who continue to have no symptoms.",
"    </p>",
"    <p>",
"     Most patients with WPW syndrome have no other underlying heart disease. When other heart disease is present, the heart may be less able to tolerate the rapid heart rate. In this case, the likelihood of serious symptoms, including chest pain and difficulty breathing due to poor heart function, increases.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      WOLFF-PARKINSON-WHITE DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     WPW is usually diagnosed with a standard electrocardiogram (ECG), but specialized testing is required in some patients.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      The electrocardiogram",
"     </span>",
"     &nbsp;&mdash;&nbsp;The WPW pattern can be detected by an ECG, even while the patient is in a normal rhythm. Conduction through the accessory pathway produces a characteristic ECG pattern. A classic finding is a short PR interval (the time for conduction between atria and ventricles) and a delta wave, which reflects early conduction (preexcitation) to the ventricles through the accessory pathway.",
"    </p>",
"    <p>",
"     If, however, most of the impulses traveling from the atria to the ventricles go through the AV node, then a short PR interval, a delta wave, and other findings associated with the WPW pattern will not be seen.",
"    </p>",
"    <p>",
"     In some people with WPW, the ECG can vary from day to day or even from hour to hour, depending upon other factors (such as adrenaline released during periods of stress or the intake of caffeine). These factors can alter the relative proportion of impulses that are conducted the accessory pathway; it is only these impulses that produce the WPW pattern.",
"    </p>",
"    <p>",
"     Diagnosis of the WPW syndrome is based upon ECG evidence of the accessory pathway and the presence of a related tachycardia.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Electrophysiologic testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;In some patients, a specialized procedure called electrophysiologic testing may be performed. This test can:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Determine the reason for tachycardia",
"      </li>",
"      <li>",
"       Identify the location of the accessory pathway",
"      </li>",
"      <li>",
"       Determine if the accessory pathway has dangerous properties",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The test is performed in an area of a hospital called an electrophysiology lab, and the patient is given a sedative medication before the procedure. The patient's oxygen levels, heart rate and rhythm, and blood pressure are monitored throughout testing.",
"    </p>",
"    <p>",
"     To perform the test, a specially trained heart rhythm specialist threads small wires (called electrode catheters), usually through a vein in the inner thigh. A vein in another area of the body may be preferred in some situations. The catheters are advanced into the heart, where they are positioned at various locations. The catheters are used to precisely monitor, or map, the heart's electrical pathways.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      WOLFF-PARKINSON-WHITE TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Most people with the WPW pattern on ECG who do not experience tachycardia do not need treatment. These patients may never develop symptoms and, in many cases, conduction via the accessory pathway spontaneously disappears as the patient grows older.",
"    </p>",
"    <p>",
"     However, some asymptomatic patients with a WPW ECG pattern (such as people with a high-risk occupation or professional athletes) are advised to undergo additional testing, including electrophysiologic testing, to determine if the accessory pathway is associated with a high risk of sudden cardiac arrest.",
"    </p>",
"    <p>",
"     Patients with WPW syndrome require treatment when or if they have an episode of tachycardia due to the serious potential risks. Treatment focuses on stopping the tachycardia and preventing it from recurring.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Stopping the tachycardia",
"     </span>",
"     &nbsp;&mdash;&nbsp;When the tachycardia is an AVRT, the tachycardia can often be stopped by interfering with the circular loop described above (see",
"     <a class=\"local\" href=\"#H7\">",
"      'Atrioventricular reentrant tachycardia'",
"     </a>",
"     above).",
"    </p>",
"    <p>",
"     This can be achieved by two simple maneuvers:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Coughing or bearing down as if having a bowel movement (called the Valsalva maneuver)",
"      </li>",
"      <li>",
"       Firmly massaging the main artery in the patient's neck (called carotid sinus pressure)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     If these measures are not effective, medications may be used to stop the tachycardia. The best medication depends upon the mechanism that is responsible. A cardiologist (heart specialist) with experience in the treatment of rhythm disturbances usually assists with treatment in this case.",
"    </p>",
"    <p>",
"     If a patient is unstable due to low blood pressure (due to the rapid heart rate) or if the medication is not immediately effective, cardioversion can be used to stop the arrhythmia. In cardioversion, electricity is discharged into the patient's heart from pads or paddles placed on the chest. The current affects the electrical charge of the heart muscle cells to restart a normal rhythm. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/10/24738?source=see_link\">",
"      \"Patient information: Cardioversion (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Preventing recurrence of the tachycardia",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are three major options for preventing recurrence of the tachycardia: radiofrequency ablation, medications, and surgery. The choice is best made with a cardiologist who has experience in treating the WPW syndrome.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Radiofrequency ablation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Radiofrequency ablation of the accessory pathway is the treatment of choice for patients with WPW syndrome. Radiofrequency ablation is performed in a hospital electrophysiology lab, similar to electrophysiology testing. The patient is given a sedative medication to reduce discomfort.",
"    </p>",
"    <p>",
"     A wire (electrode catheter) is advanced into the heart and positioned within the chambers of the heart using fluoroscopy (low energy x-rays). Radiofrequency energy (low-voltage, high frequency electricity) is targeted toward the area, damaging the pathway and preventing it from conducting impulses. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/31/14834?source=see_link\">",
"      \"Patient information: Radiofrequency catheter ablation for the heart (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     When performed by experienced specialists, ablation cures the WPW syndrome over 95 percent of the time. However, some patients have multiple accessory pathways. In these patients, one of the pathways may not be detected and ablated during the initial procedure, and the arrhythmia may reoccur. When this happens, the ablation procedure can be repeated, generally with very good results.",
"    </p>",
"    <p>",
"     The risk of a major complication is low, about 3 percent, with the primary risks being damage to the blood vessels or nerves in the thigh, bleeding, infection, perforation of the heart, and heart block requiring a pacemaker.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;Surgery is another method to disconnect the WPW pathway. The success rate for surgical ablation is close to 100 percent and the complication rate is low. However, radiofrequency ablation is a less invasive option; as a result, surgery is now rarely performed. Surgical ablation may be preferred if the patient is undergoing cardiac surgery for other reasons (such as coronary artery bypass surgery or valve surgery) and is recommended when radiofrequency ablation and medications are not effective. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/62/31717?source=see_link\">",
"      \"Patient information: Coronary artery bypass graft surgery (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h3\">",
"      Medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Medications can prevent recurrences of the tachycardia in some patients. Patients who have tachycardia infrequently may be given medications to use during an episode. They may also be taught to perform maneuvers (eg, Valsalva) that can stop the tachycardia. Other patients need to take daily medication to prevent the arrhythmia.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H181\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11570141\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/56/23427?source=see_link\">",
"      Patient information: Wolff-Parkinson-White syndrome (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/54/13154?source=see_link\">",
"      Patient information: Radiofrequency catheter ablation for the heart (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/17/33042?source=see_link\">",
"      Patient information: Vagal maneuvers and their responses (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11570175\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/31/14834?source=see_link\">",
"      Patient information: Radiofrequency catheter ablation for the heart (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/16/261?source=see_link\">",
"      Patient information: Atrial fibrillation (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/10/24738?source=see_link\">",
"      Patient information: Cardioversion (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/62/31717?source=see_link\">",
"      Patient information: Coronary artery bypass graft surgery (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39256?source=see_link\">",
"      Anatomy, pathophysiology and localization of accessory pathways in the preexcitation syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/61/17370?source=see_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15305?source=see_link\">",
"      Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24311?source=see_link\">",
"      Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Heart, Lung, and Blood Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nhlbi.nih.gov/\">",
"      www.nhlbi.nih.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Heart Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.americanheart.org/\">",
"      www.americanheart.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?8/50/8995/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 3, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?8/50/8995?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/8995/abstract/1\">",
"      Wellens HJ. Should catheter ablation be performed in asymptomatic patients with Wolff-Parkinson-White syndrome? When to perform catheter ablation in asymptomatic patients with a Wolff-Parkinson-White electrocardiogram. Circulation 2005; 112:2201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/8995/abstract/2\">",
"      Pappone C, Santinelli V. Should catheter ablation be performed in asymptomatic patients with Wolff-Parkinson-White syndrome? Catheter ablation should be performed in asymptomatic patients with Wolff-Parkinson-White syndrome. Circulation 2005; 112:2207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/8995/abstract/3\">",
"      Hogenhuis W, Stevens SK, Wang P, et al. Cost-effectiveness of radiofrequency ablation compared with other strategies in Wolff-Parkinson-White syndrome. Circulation 1993; 88:437.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f8_50_8995=[""].join("\n");
var outline_f8_50_8995=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           THE HEART",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           CAUSES OF WOLFF-PARKINSON-WHITE SYNDROME",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           WOLFF-PARKINSON-WHITE SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           WOLFF-PARKINSON-WHITE DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           WOLFF-PARKINSON-WHITE TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/14/11495\" title=\"figure 1\">",
"           Cardiac anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/20/4420\" title=\"figure 2\">",
"           Heart conduction system PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/32/42500\" title=\"figure 3\">",
"           Heart conduction WPW PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f8_50_8996="Cefotetan: Patient drug information";
var content_f8_50_8996=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cefotetan: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/55/17269?source=see_link\">",
"     see \"Cefotetan: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/43/9908?source=see_link\">",
"     see \"Cefotetan: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701742",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cefotetan or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701015",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If this drug or alike drugs caused low red blood cell counts before.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into a vein for a period of time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695961",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be given at home.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10025001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699187",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to store closely.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11318 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.122.249.114-59E8FFCE15-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_50_8996=[""].join("\n");
var outline_f8_50_8996=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024998\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024997\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025002\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025003\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025005\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025000\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025001\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025006\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025007\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/55/17269?source=related_link\">",
"      Cefotetan: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/43/9908?source=related_link\">",
"      Cefotetan: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_50_8997="Interstitial lung disease in amyopathic dermatomyositis";
var content_f8_50_8997=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F87914&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F87914&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 491px\">",
"   <div class=\"ttl\">",
"    Interstitial lung disease in amyopathic dermatomyositis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 471px; height: 461px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest computed tomography (CT) showing increased reticular markings and ground glass opacities at the lung bases in a patient with amyopathic dermatomyositis. More cephalad cuts showed a pneumomediastinum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_50_8997=[""].join("\n");
var outline_f8_50_8997=null;
var title_f8_50_8998="Seborrheic dermatitis scalp 2";
var content_f8_50_8998=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76985&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76985&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Seborrheic dermatitis of the scalp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_50_8998=[""].join("\n");
var outline_f8_50_8998=null;
var title_f8_50_8999="Pulmonary KS high";
var content_f8_50_8999=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F77671&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F77671&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary Kaposi sarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 403px; height: 262px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power photomicrograph shows a perivenular infiltrate of Kaposi sarcoma with a mixture of spindle cells, inflammatory cells, and ectatic vascular spaces.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Colby TV, Koss MN, Travis WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_50_8999=[""].join("\n");
var outline_f8_50_8999=null;
var title_f8_50_9000="Fixed drug eruption";
var content_f8_50_9000=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Fixed drug eruption",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/50/9000/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/50/9000/contributors\">",
"     Tetsuo Shiohara, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/50/9000/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/50/9000/contributors\">",
"     Maja Mockenhaupt, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/50/9000/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/50/9000/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/50/9000/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1633148\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fixed drug eruption (FDE) is a distinctive type of cutaneous drug reaction that characteristically recurs in the same locations upon reexposure to the offending drug. Acute FDE usually presents with a single or a small number of dusky red or violaceous plaques that resolve leaving postinflammatory hyperpigmentation (",
"    <a class=\"graphic graphic_picture graphicRef86671 graphicRef52192 graphicRef73678 \" href=\"UTD.htm?32/51/33594\">",
"     picture 1A-C",
"    </a>",
"    ). Rare severe atypical variants of FDE, including multiple, nonpigmenting, and generalized bullous variants, share clinical features with Stevens-Johnson",
"    <span class=\"nowrap\">",
"     syndrome/toxic",
"    </span>",
"    epidermal necrolysis.",
"   </p>",
"   <p>",
"    FDE will be discussed in this topic. Other types of drug eruptions are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=see_link\">",
"     \"Drug eruptions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24360?source=see_link\">",
"     \"Exanthematous (morbilliform) drug eruption\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/48/3848?source=see_link\">",
"     \"Lichenoid drug eruption (drug-induced lichen planus)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=see_link\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1633155\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous skin reactions occur in approximately 2 to 3 percent of patients taking drugs. Fixed drug eruptions (FDE) are less common than exanthematous (morbilliform) eruptions, which are estimated to account for up to 95 percent of cutaneous drug reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9000/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. FDEs occur in both sexes and in all age groups; in children, FDEs account for 14 to 22 percent of cutaneous drug reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9000/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1633162\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56452388\">",
"    <span class=\"h2\">",
"     Eliciting drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many drugs may induce fixed drug eruptions (FDE). The frequency with which individual drugs cause FDE varies over time and from country to country, depending upon drug availability and rates of consumption. Drugs most frequently associated with FDE include [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9000/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Antibacterial agents (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      , tetracyclines, penicillins, quinolones,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      NSAIDs (acetylsalicylic acid,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/63/41976?source=see_link\">",
"       mefenamic acid",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       Acetaminophen (paracetamol)",
"      </a>",
"      &nbsp;",
"     </li>",
"     <li>",
"      Barbiturates",
"     </li>",
"     <li>",
"      Antimalarials",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1633169\">",
"    <span class=\"h2\">",
"     Immunologic mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraepidermal CD8",
"    <sup>",
"     +",
"    </sup>",
"    T cells are thought to have a key role in mediating the localized epidermal lesion that characterizes FDE [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9000/abstract/9\">",
"     9",
"    </a>",
"    ]. CD8",
"    <sup>",
"     +",
"    </sup>",
"    T cells with an effector&ndash;memory phenotype are abundantly detected along the dermoepidermal junction in established FDE lesions and persist in resting FDE lesions long after the clinical resolution (",
"    <a class=\"graphic graphic_picture graphicRef86641 graphicRef86642 \" href=\"UTD.htm?31/48/32521\">",
"     picture 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9000/abstract/9-13\">",
"     9-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sequential analysis of FDE lesions before and after rechallenge with the causative drug demonstrated that intraepidermal CD8",
"    <sup>",
"     +",
"    </sup>",
"    T cells are directly involved in epidermal damage (",
"    <a class=\"graphic graphic_picture graphicRef86643 \" href=\"UTD.htm?30/2/30759\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9000/abstract/14\">",
"     14",
"    </a>",
"    ]. CD8",
"    <sup>",
"     +",
"    </sup>",
"    T cells remain quiescent but in a primed state in healed FDE lesions unless the causative drug is readministered. Upon rechallenge, CD8",
"    <sup>",
"     +",
"    </sup>",
"    T cells are activated to release interferon gamma and cytotoxic granules such as granzyme B and perforin [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9000/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Mast cells also contribute to the activation of intraepidermal T cells via the induction of cell adhesion molecules on the surrounding keratinocytes, through the action of tumor necrosis factor alpha [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9000/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The activation of intraepidermal T cells is sufficient for triggering the reaction but insufficient to cause the extensive tissue damage observed in fully evolved lesions. Cytokines",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    adhesion molecule-mediated recruitment of CD4",
"    <sup>",
"     +",
"    </sup>",
"    T cells, CD8",
"    <sup>",
"     +",
"    </sup>",
"    T cells, and neutrophils may contribute to tissue damage in fully developed FDE lesions.",
"   </p>",
"   <p>",
"    In the late stage of the immune response, CD4",
"    <sup>",
"     +",
"    </sup>",
"    CD25",
"    <sup>",
"     +",
"    </sup>",
"    Foxp3",
"    <sup>",
"     +",
"    </sup>",
"    regulatory T (Treg) cells are recruited into the lesion and participate in the homeostatic control of the immune reaction. The majority of the expanded or activated cell populations responsible for epidermal damage are eventually removed from tissue by apoptosis. However, a proportion of intraepidermal CD8",
"    <sup>",
"     +",
"    </sup>",
"    T cells is prevented from undergoing apoptosis by IL-15 secreted by basal keratinocytes and persists at the injury site as a memory T cell population [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9000/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1512201\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologically, FDE is the prototype of a lichenoid tissue reaction with pigmentary incontinence (accumulation of melanin in the upper dermis and dermal macrophages) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9000/abstract/16\">",
"     16",
"    </a>",
"    ]. In florid lesions, major features include hydropic degeneration of basal keratinocytes, dyskeratotic cells scattered in the epidermis, lymphocytic infiltration of the dermis, and dermal melanophages. The hair follicles and acrosyringia (the intraepidermal portions of the sweat gland duct) also may be involved. In some lesions, the exocytosis of lymphocytes is marked, mimicking Pautrier microabscesses of mycosis fungoides.",
"   </p>",
"   <p>",
"    Healed hyperpigmented lesions show pigmentary incontinence and a mild perivascular inflammatory infiltrate.",
"   </p>",
"   <p>",
"    The pathologic changes occurring in a resting lesion after reexposure to the offending drug have been documented by sequential biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9000/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Resting FDE lesions are characterized by a small number of resident CD8",
"      <sup>",
"       +",
"      </sup>",
"      lymphocytes aligned along the epidermal side of the dermoepidermal junction (",
"      <a class=\"graphic graphic_picture graphicRef86641 graphicRef86642 \" href=\"UTD.htm?31/48/32521\">",
"       picture 2A-B",
"      </a>",
"      ). The overlying epidermis appears normal (",
"      <a class=\"graphic graphic_picture graphicRef86643 \" href=\"UTD.htm?30/2/30759\">",
"       picture 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Two to three hours after rechallenge, the lymphocytes originally adhering to the basal layer move upward to the lower one-half of the epidermis while preserving the epidermal structures.",
"     </li>",
"     <li>",
"      Twenty-four to 48 hours after rechallenge, the typical changes of interface dermatitis can be seen, including vacuolar degeneration of keratinocytes, dermal lymphocytic infiltrate extending upward into the epidermis, and dermal pigmentary incontinence. The extent of epidermal damage is highly variable, ranging from intercellular edema and dyskeratotic cells scattered in the epidermis to confluent epidermal necrosis resembling TEN.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several atypical histologic reaction patterns have been described in FDE, including a neutrophilic reaction, leukocytoclastic vasculitis, and nonpigmenting FDE (NPFDE) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9000/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. In NPFDE, the epidermal changes are mild or absent and a superficial perivascular infiltrate of lymphocytes and eosinophils without melanophages is seen in the upper reticular dermis. In generalized bullous FDE, the histologic features of the blister area closely resemble those seen in",
"    <span class=\"nowrap\">",
"     SJS/TEN",
"    </span>",
"    (full-thickness necrosis of the epidermis without pigmentary incontinence) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9000/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1633176\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fixed drug eruption (FDE) typically presents with well demarcated, round to oval, dusky red to",
"    <span class=\"nowrap\">",
"     brown/black",
"    </span>",
"    macules that may evolve into edematous plaques with or without vesiculation or blistering (",
"    <a class=\"graphic graphic_picture graphicRef67733 graphicRef52192 graphicRef86671 \" href=\"UTD.htm?37/46/38634\">",
"     picture 1A-B, 1D",
"    </a>",
"    ). Lesions are usually solitary, buy may occur in small groups.",
"   </p>",
"   <p>",
"    Systemic symptoms, such as fever and malaise, are usually absent. Pruritus and a burning or stinging sensation are common. However, the estimated frequency of these findings is not known because they are not consistently reported in case series.",
"   </p>",
"   <p>",
"    FDE may occur anywhere on the body. Sites of predilection include the lips, genitalia, perianal area, hands, and feet [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9000/abstract/22\">",
"     22",
"    </a>",
"    ]. On mucosal areas, erosions and ulcers may develop (",
"    <a class=\"graphic graphic_picture graphicRef65991 \" href=\"UTD.htm?10/16/10499\">",
"     picture 1E",
"    </a>",
"    ). FDE occasionally develops at the site of an antecedent trauma (eg, insect bite, burn, venipuncture) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9000/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute lesions generally appear 30 minutes to 8 hours after drug administration, but can occur up to two weeks after drug exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9000/abstract/7,25\">",
"     7,25",
"    </a>",
"    ]. After discontinuation of the offending drug, lesions resolve spontaneously in 7 to 10 days, leaving a persistent",
"    <span class=\"nowrap\">",
"     gray/brown",
"    </span>",
"    or slate gray postinflammatory hyperpigmentation (",
"    <a class=\"graphic graphic_picture graphicRef73678 \" href=\"UTD.htm?19/54/20321\">",
"     picture 1C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Upon reexposure to the offending drug, lesions typically recur in the same site, but new lesions may develop elsewhere (",
"    <a class=\"graphic graphic_picture graphicRef86644 \" href=\"UTD.htm?9/60/10178\">",
"     picture 4",
"    </a>",
"    ). After one or more localized eruptions, FDE rarely may evolve into a bullous generalized form mimicking Stevens-Johnson",
"    <span class=\"nowrap\">",
"     syndrome/toxic",
"    </span>",
"    epidermal necrolysis (",
"    <a class=\"graphic graphic_picture graphicRef86645 \" href=\"UTD.htm?21/7/21619\">",
"     picture 5",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H1511943\">",
"     'Generalized FDE'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H1639622\">",
"     'Generalized bullous FDE'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    FDE can be induced by drugs with a chemical structure similar to the causative drug (cross-reactivity). There are isolated reports of FDE lesions reactivated by chemically unrelated drugs, a phenomenon known as polysensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9000/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1633183\">",
"    <span class=\"h1\">",
"     CLINICAL VARIANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fixed drug eruption (FDE) rarely may present with atypical features that mimic other skin diseases such as erythema multiforme, Stevens-Johnson",
"    <span class=\"nowrap\">",
"     syndrome/toxic",
"    </span>",
"    epidermal necrolysis",
"    <span class=\"nowrap\">",
"     (SJS/TEN),",
"    </span>",
"    cellulitis, paronychia, neutrophilic dermatosis, or large-plaque parapsoriasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54984555\">",
"    <span class=\"h2\">",
"     Erythema multiforme-like FDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;FDE may present with targetoid lesions that mimic erythema multiforme (",
"    <a class=\"graphic graphic_picture graphicRef86682 \" href=\"UTD.htm?9/60/10179\">",
"     picture 6",
"    </a>",
"    ). In contrast to erythema multiforme, these lesions have only two concentric zones of color with a darker, dusky hue in the center. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37672?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathogenesis, clinical features, and diagnosis of erythema multiforme\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1511943\">",
"    <span class=\"h2\">",
"     Generalized FDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical lesions are multiple and disseminated and involve the trunk and extremities, sparing the mucosal and the semi-mucosal areas (",
"    <a class=\"graphic graphic_picture graphicRef86651 \" href=\"UTD.htm?29/17/29973\">",
"     picture 7",
"    </a>",
"    ). Generalized FDE may be difficult to distinguish clinically and histologically from erythema dyschromicum perstans (",
"    <a class=\"graphic graphic_picture graphicRef86650 \" href=\"UTD.htm?31/2/31778\">",
"     picture 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9000/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1639622\">",
"    <span class=\"h2\">",
"     Generalized bullous FDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generalized bullous fixed drug eruption (GBFDE) is an extremely rare form of FDE characterized by widespread red or brown macules or plaques with overlying large flaccid bullae (",
"    <a class=\"graphic graphic_picture graphicRef86645 \" href=\"UTD.htm?21/7/21619\">",
"     picture 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9000/abstract/29\">",
"     29",
"    </a>",
"    ]. Systemic symptoms, such as fever, malaise, or arthralgias may be present.",
"   </p>",
"   <p>",
"    Patients with GBFDE can be misdiagnosed as having",
"    <span class=\"nowrap\">",
"     SJS/TEN,",
"    </span>",
"    but in GBFDE mucosal involvement is usually absent or mild and the clinical course is favorable with rapid resolution in 7 to 14 days after drug discontinuation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9000/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the prognosis of GBFDE may be unfavorable in older patients, particularly in those with comorbidities. In a case-control study including patients with GBFDE (age range 68 to 84 years) and matched controls with",
"    <span class=\"nowrap\">",
"     SJS/TEN,",
"    </span>",
"    the mortality rate among patients with GBFDE was 22 percent, similar to that observed among patients with",
"    <span class=\"nowrap\">",
"     SJS/TEN",
"    </span>",
"    with the same amount of skin detachment [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9000/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=see_link\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1639685\">",
"    <span class=\"h2\">",
"     Nonpigmenting FDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonpigmenting fixed drug eruptions (NPFDE) have been described in a small number of patients, most often in association with the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19190?source=see_link\">",
"     pseudoephedrine",
"    </a>",
"    . NPFDE presents with large solitary or multiple, well-circumscribed erythematous plaques that resolve without postinflammatory hyperpigmentation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9000/abstract/17,33\">",
"     17,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A severe form of NPFDE, characterized by disseminated, large, symmetrical plaques and systemic symptoms may be misdiagnosed as",
"    <span class=\"nowrap\">",
"     SJS/TEN.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1511752\">",
"    <span class=\"h2\">",
"     Other variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other rare forms of FDE have been described in isolated reports and include [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9000/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      FDE presenting with acute paronychia",
"     </li>",
"     <li>",
"      FDE presenting with a linear distribution reminiscent of herpes zoster",
"     </li>",
"     <li>",
"      FDE mimicking large-plaque parapsoriasis &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1633197\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1512454\">",
"    <span class=\"h2\">",
"     Clinical",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of fixed drug eruption (FDE) in its typical presentation is usually straightforward, based upon lesion morphology and history:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Single or a small number of round or oval, demarcated, erythematous or hyperpigmented macules or plaques located most often on the lips, genitalia, and extremities (",
"      <a class=\"graphic graphic_picture graphicRef86671 graphicRef52192 graphicRef65991 \" href=\"UTD.htm?35/16/36106\">",
"       picture 1A-B, 1E",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      History of drug intake in the hours or days preceding the eruption. The medication history should be taken in great detail and include all types of medications and routes of administration, since patients tend to overlook medications that they have been taking sporadically over years. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/62/24554?source=see_link&amp;anchor=H17#H17\">",
"       \"An approach to the patient with drug allergy\", section on 'Identification of the suspect drug'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      History of recurrence in the same sites following the administration of the same drug or a chemically related drug.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56451481\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A skin biopsy for histopathologic examination may be warranted in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Unusual clinical presentation (eg, generalized or bullous FDE) that raises the suspicion of severe drug reaction",
"     </li>",
"     <li>",
"      Presence of systemic symptoms (eg, fever, malaise)",
"     </li>",
"     <li>",
"      When the diagnosis is uncertain (eg, negative medication history)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Histologic findings that support the diagnosis of FDE include hydropic degeneration of the basal layer, pigmentary incontinence, single necrotic keratinocytes (dyskeratotic cells) in the upper layers of the epidermis, and a dermal inflammatory infiltrate predominantly composed of lymphocytes. In generalized bullous FDE, the examination of a biopsy taken from the blister area reveals full-thickness necrosis of the epidermis without pigmentary incontinence. (See",
"    <a class=\"local\" href=\"#H1512201\">",
"     'Histopathology'",
"    </a>",
"    above.).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1512461\">",
"    <span class=\"h2\">",
"     Provocation tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic (oral challenge) and topical (patch testing) provocation tests can be performed to identify the culprit drug when history is unclear or multiple medications are suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9000/abstract/6,15\">",
"     6,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56452116\">",
"    <span class=\"h3\">",
"     Systemic provocation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral challenge with the suspected drug induces the reactivation of a resting FDE lesion. In most cases, oral challenge is preferred to patch testing because it reproduces the conditions of exposure.",
"   </p>",
"   <p>",
"    Oral challenge is contraindicated in patients with a history of generalized FDE. In patients without generalized FDE, oral challenge is considered relatively safe because the cutaneous response is localized and the risk of a severe reaction is low. In a series of 450 patients with FDE, oral challenge with the suspected drug produced pruritus in 10 percent of patients, fever in 0.9 percent, and generalized urticaria in 0.7 percent, but no more severe adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9000/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, neither the appropriate dose of the suspected drug sufficient to induce a mild reaction nor the timing of the test after the resolution of the initial eruption has been standardized. Our approach is to perform the test two to four weeks after the resolution of the eruption, starting with one-tenth of a single therapeutic dose and gradually increasing the amount every 12 to 24 hours up to one single therapeutic dose. Others may use a different approach. In a prospective series of 93 patients with FDE, oral challenge was started with one-half of the therapeutic dose; if no reaction was elicited, a full dose was given [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9000/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A flare-up reaction occurring within 30 minutes to 8 hours of the oral challenge within a resting FDE lesion is considered a positive test response (",
"    <a class=\"graphic graphic_picture graphicRef86644 \" href=\"UTD.htm?9/60/10178\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9000/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1512468\">",
"    <span class=\"h3\">",
"     Patch testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patch testing also can be used to confirm the diagnosis if oral testing cannot be performed (eg, patients with a history of generalized FDE) or if the patient or parent refuses an oral challenge. Patch testing can be performed by applying the suspected drug to an old FDE lesion to elicit a local reaction. Patch testing is generally considered to be safe because the reaction is localized.",
"   </p>",
"   <p>",
"    There is no standardized method for patch testing in FDE. Various drug concentrations and application modalities (eg, single open, repeated open, or occlusive) have been used in several series of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9000/abstract/7,8,38,39\">",
"     7,8,38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Our approach is to use the commercially available drug mixed in petrolatum or diluted in water at the concentration of approximately 10 to 20 percent. The drug is applied to the target area in open or occlusive modality. The development of erythema with or without induration that starts within 24 hours and lasts for at least 6 hours is considered a positive reaction (",
"    <a class=\"graphic graphic_picture graphicRef86673 \" href=\"UTD.htm?26/56/27522\">",
"     picture 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9000/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    False negative results may occur when testing drugs with limited ability to penetrate into the skin or when FDE is caused by a drug metabolite [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9000/abstract/15\">",
"     15",
"    </a>",
"    ]. False positive reactions may be observed with drug concentrations higher than 20 percent due to patch test sensitization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/31/28150?source=see_link&amp;anchor=H2463525#H2463525\">",
"     \"Patch testing\", section on 'Active sensitization'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1633204\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of fixed drug eruption (FDE) includes:",
"   </p>",
"   <p>",
"    <strong>",
"     Erythema multiforme",
"    </strong>",
"    &ndash; Erythema multiforme (EM) is rarely induced by drugs. The number, distribution, and morphology of lesions help to differentiate EM from FDE. Target lesions consisting of three components (a dusky central area or blister, a dark red inflammatory zone surrounded by a pale ring of edema, and an erythematous halo) are the hallmark of EM (",
"    <a class=\"graphic graphic_picture graphicRef79955 \" href=\"UTD.htm?18/53/19283\">",
"     picture 10",
"    </a>",
"    ). They are generally numerous and symmetrically distributed on the extremities. Mucosal lesions are present in many cases (EM majus) (",
"    <a class=\"graphic graphic_picture graphicRef62370 \" href=\"UTD.htm?13/14/13540\">",
"     picture 11",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37672?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathogenesis, clinical features, and diagnosis of erythema multiforme\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <strong>",
"     Stevens-Johnson",
"     <span class=\"nowrap\">",
"      Syndrome/Toxic",
"     </span>",
"     epidermal necrolysis",
"    </strong>",
"    &ndash; Generalized bullous fixed drug eruption (GBFDE) may sometimes be difficult to differentiate from Stevens-Johnson",
"    <span class=\"nowrap\">",
"     syndrome/toxic",
"    </span>",
"    epidermal necrolysis",
"    <span class=\"nowrap\">",
"     (SJS/TEN)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_picture graphicRef67632 \" href=\"UTD.htm?24/48/25345\">",
"     picture 12",
"    </a>",
"    ). However, in",
"    <span class=\"nowrap\">",
"     SJS/TEN,",
"    </span>",
"    lesions have a less defined border than FDE lesions with a tendency to coalesce; mucous membranes (eg, oral, conjunctival) are involved in over 90 percent of cases (",
"    <a class=\"graphic graphic_picture graphicRef73805 \" href=\"UTD.htm?30/7/30836\">",
"     picture 13",
"    </a>",
"    ); and patients have systemic symptoms and rapid disease progression.",
"   </p>",
"   <p>",
"    The histologic features in the early stage of",
"    <span class=\"nowrap\">",
"     SJS/TEN",
"    </span>",
"    are similar to those of GBFDE; however, as the disease progresses, full thickness epidermal necrosis with skin detachment above the basement membrane becomes evident. In most patients, GBFDE resolves rapidly in 7 to 14 days after drug discontinuation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9000/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. The course of",
"    <span class=\"nowrap\">",
"     SJS/TEN",
"    </span>",
"    is generally longer than in GBFDE and complications and sequelae (eg, sepsis, organ failure, late ophthalmic and pulmonary complications) are frequent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33801?source=see_link&amp;anchor=H20#H20\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae\", section on 'Long-term sequelae'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=see_link\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"    </a>",
"    .) &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    <strong>",
"     Bullous pemphigoid",
"    </strong>",
"    &ndash;",
"    <strong>",
"    </strong>",
"    Bullous pemphigoid (BP) typically occurs in patients older than 60 years and is frequently preceded by a prodromal phase characterized by pruritic inflammatory plaques resembling urticaria. The typical skin lesions of BP are large, tense blisters that rupture and heal spontaneously without scarring (",
"    <a class=\"graphic graphic_picture graphicRef70352 \" href=\"UTD.htm?21/24/21892\">",
"     picture 14",
"    </a>",
"    ). Histology reveals a subepidermal blister with a dermal infiltrate of eosinophils, neutrophils, and lymphocytes (",
"    <a class=\"graphic graphic_picture graphicRef66267 \" href=\"UTD.htm?43/15/44279\">",
"     picture 15",
"    </a>",
"    ). Direct immunofluorescence of perilesional skin shows linear IgG",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    linear C3 staining along the basement membrane zone (",
"    <a class=\"graphic graphic_picture graphicRef53466 \" href=\"UTD.htm?42/47/43775\">",
"     picture 16",
"    </a>",
"    ), which is absent in FDE. The diagnosis of BP can be confirmed by enzyme-linked immunosorbent assay demonstrating circulating autoantibodies against the bullous pemphigoid antigens BP180 NC16A domain and BP230. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=see_link&amp;anchor=H784094#H784094\">",
"     \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=see_link&amp;anchor=H20007006#H20007006\">",
"     \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <strong>",
"     Large-plaque parapsoriasis",
"    </strong>",
"    &ndash; Large-plaque parapsoriasis may resemble the pigmented patches of FDE (",
"    <a class=\"graphic graphic_picture graphicRef68028 graphicRef86681 \" href=\"UTD.htm?14/23/14713\">",
"     picture 17A-B",
"    </a>",
"    ). A skin biopsy is necessary to clarify the diagnosis. Histology reveals epidermal hyperplasia (or atrophy in poikilodermatous areas) and a dermal lymphocytic infiltrate that can become band-like at the dermal epidermal junction and show epidermotropism (exocytosis of small lymphocytes into the epidermis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1633253\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54984425\">",
"    <span class=\"h2\">",
"     Drug withdrawal and avoidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Discontinuation of the offending drug is the most important aspect of management of FDE. After drug discontinuation, lesions resolve without treatment in a few days leaving postinflammatory hyperpigmentation.",
"   </p>",
"   <p>",
"    Patients should be advised to avoid the offending drug and chemically related drugs and be provided with a written list of the generic and brand names of the culprit drug and possibly of cross-reactive drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54984433\">",
"    <span class=\"h2\">",
"     Symptomatic treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of FDE is largely symptomatic and aimed at the relief of pruritus. The efficacy of symptomatic therapies for the treatment of FDE has not been evaluated in randomized trials. However, their use is based on clinical experience and indirect evidence of benefit in patients other pruritic skin conditions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6058?source=see_link\">",
"     \"Pruritus: Overview of management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with single or a small number of lesions, we suggest medium to high potency topical corticosteroids (groups one to three (",
"      <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"       table 1",
"      </a>",
"      )) and systemic antihistamines. Topical corticosteroids are applied two times per day for 7 to 10 days. Oral H1 antihistamines are generally used, including:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"       Diphenhydramine",
"      </a>",
"      &ndash; 25 to 50 mg orally every four to six hours for adults and children &ge;12 years; 12.5 to 25 mg orally every four to six hours for children 6 to 11 years; and 6.25 mg orally every four to six hours for children 2 to 5 years. Diphenhydramine is continued until pruritus subsides.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"       Hydroxyzine",
"      </a>",
"      &ndash; 25 mg orally three to four times per day for adults and children &ge;6 years; 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day orally divided every six to eight hours for children &lt;6 years. Hydroxyzine is continued until pruritus subsides.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with generalized FDE or generalized bullous FDE, particularly if systemic symptoms are present, a short course of moderate dose systemic corticosteroids (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      0.5 to 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for three to five days) may be beneficial. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1633260\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fixed drug eruption (FDE) is a cutaneous drug reaction that characteristically recurs in the same locations upon reexposure to the offending drug. Antibacterial sulfonamides, antibiotics, nonsteroidal antiinflammatory drugs, analgesics, and hypnotics are the most frequent causes of FDE. (See",
"      <a class=\"local\" href=\"#H1633148\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H56452388\">",
"       'Eliciting drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      FDE typically presents with solitary round to oval, dusky red to",
"      <span class=\"nowrap\">",
"       brown/black",
"      </span>",
"      macules that may evolve into edematous plaques or bullae (",
"      <a class=\"graphic graphic_picture graphicRef52192 graphicRef86671 graphicRef67733 \" href=\"UTD.htm?37/45/38618\">",
"       picture 1A-B, 1D",
"      </a>",
"      ). Sites of predilection include the lips, genitalia, perianal area, and extremities. Acute lesions usually develop 30 minutes to 8 hours after drug administration and resolve spontaneously in 7 to 10 days, leaving a persistent",
"      <span class=\"nowrap\">",
"       gray/brown",
"      </span>",
"      or slate gray postinflammatory hyperpigmentation (",
"      <a class=\"graphic graphic_picture graphicRef73678 \" href=\"UTD.htm?19/54/20321\">",
"       picture 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1633176\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In rare cases, FDE may present with atypical features, including generalized bullous FDE and nonpigmenting FDE that mimic more severe drug eruptions such as Stevens-Johnson",
"      <span class=\"nowrap\">",
"       syndrome/toxic",
"      </span>",
"      epidermal necrolysis (",
"      <a class=\"graphic graphic_picture graphicRef86645 \" href=\"UTD.htm?21/7/21619\">",
"       picture 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1633183\">",
"       'Clinical variants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of fixed drug eruption (FDE) in its typical presentation is usually straightforward, based upon lesion morphology and history. Histologic examination of a skin biopsy is helpful in establishing the diagnosis in cases with unusual clinical features. (See",
"      <a class=\"local\" href=\"#H1512454\">",
"       'Clinical'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H56451481\">",
"       'Biopsy'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Systemic or topical provocation tests may be helpful in identifying the culprit drug when history is unclear or multiple medications are suspected. (See",
"      <a class=\"local\" href=\"#H1512461\">",
"       'Provocation tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Discontinuation and avoidance of the offending drug is the most important aspect of management of FDE. Symptomatic treatment of the acute eruption may include medium to high potency topical corticosteroids (groups one to three (",
"      <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"       table 1",
"      </a>",
"      )) and systemic antihistamines. (See",
"      <a class=\"local\" href=\"#H54984425\">",
"       'Drug withdrawal and avoidance'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H54984433\">",
"       'Symptomatic treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9000/abstract/1\">",
"      Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA 1986; 256:3358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9000/abstract/2\">",
"      Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol 2001; 137:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9000/abstract/3\">",
"      Lee AY. Fixed drug eruptions. Incidence, recognition, and avoidance. Am J Clin Dermatol 2000; 1:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9000/abstract/4\">",
"      Khaled A, Kharfi M, Ben Hamida M, et al. Cutaneous adverse drug reactions in children. A series of 90 cases. Tunis Med 2012; 90:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9000/abstract/5\">",
"      Sharma VK, Dhar S. Clinical pattern of cutaneous drug eruption among children and adolescents in north India. Pediatr Dermatol 1995; 12:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9000/abstract/6\">",
"      Mahboob A, Haroon TS. Drugs causing fixed eruptions: a study of 450 cases. Int J Dermatol 1998; 37:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9000/abstract/7\">",
"      Brahimi N, Routier E, Raison-Peyron N, et al. A three-year-analysis of fixed drug eruptions in hospital settings in France. Eur J Dermatol 2010; 20:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9000/abstract/8\">",
"      Nnoruka EN, Ikeh VO, Mbah AU. Fixed drug eruption in Nigeria. Int J Dermatol 2006; 45:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9000/abstract/9\">",
"      Shiohara T, Mizukawa Y. Fixed drug eruption: a disease mediated by self-inflicted responses of intraepidermal T cells. Eur J Dermatol 2007; 17:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9000/abstract/10\">",
"      Shiohara T, Moriya N. Epidermal T cells: their functional role and disease relevance for dermatologists. J Invest Dermatol 1997; 109:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9000/abstract/11\">",
"      Shiohara T, Mizukawa Y, Teraki Y. Pathophysiology of fixed drug eruption: the role of skin-resident T cells. Curr Opin Allergy Clin Immunol 2002; 2:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9000/abstract/12\">",
"      Komatsu T, Moriya N, Shiohara T. T cell receptor (TCR) repertoire and function of human epidermal T cells: restricted TCR V alpha-V beta genes are utilized by T cells residing in the lesional epidermis in fixed drug eruption. Clin Exp Immunol 1996; 104:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9000/abstract/13\">",
"      Mizukawa Y, Yamazaki Y, Teraki Y, et al. Direct evidence for interferon-gamma production by effector-memory-type intraepidermal T cells residing at an effector site of immunopathology in fixed drug eruption. Am J Pathol 2002; 161:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9000/abstract/14\">",
"      Mizukawa Y, Yamazaki Y, Shiohara T. In vivo dynamics of intraepidermal CD8+ T cells and CD4+ T cells during the evolution of fixed drug eruption. Br J Dermatol 2008; 158:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9000/abstract/15\">",
"      Shiohara T. Fixed drug eruption: pathogenesis and diagnostic tests. Curr Opin Allergy Clin Immunol 2009; 9:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9000/abstract/16\">",
"      Shiohara T, Mizukawa Y. The immunological basis of lichenoid tissue reaction. Autoimmun Rev 2005; 4:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9000/abstract/17\">",
"      Shelley WB, Shelley ED. Nonpigmenting fixed drug eruption as a distinctive reaction pattern: examples caused by sensitivity to pseudoephedrine hydrochloride and tetrahydrozoline. J Am Acad Dermatol 1987; 17:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9000/abstract/18\">",
"      Agnew KL, Oliver GF. Neutrophilic fixed drug eruption. Australas J Dermatol 2001; 42:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9000/abstract/19\">",
"      Ozkaya E, B&uuml;y&uuml;kbabani N. Neutrophilic fixed drug eruption caused by naproxen: a real entity or a stage in the histopathologic evolution of the disease? J Am Acad Dermatol 2005; 53:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9000/abstract/20\">",
"      Harris A, Burge SM. Vasculitis in a fixed drug eruption due to paracetamol. Br J Dermatol 1995; 133:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9000/abstract/21\">",
"      Mockenhaupt M. Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. J Dtsch Dermatol Ges 2009; 7:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9000/abstract/22\">",
"      Korkij W, Soltani K. Fixed drug eruption. A brief review. Arch Dermatol 1984; 120:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9000/abstract/23\">",
"      Mizukawa Y, Shiohara T. Trauma-localized fixed drug eruption: involvement of burn scars, insect bites and venipuncture sites. Dermatology 2002; 205:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9000/abstract/24\">",
"      Shiohara T, Mizukawa Y. Recall phenomenon: some skin-resident cells remember previous insults. Dermatology 2003; 207:127.",
"     </a>",
"    </li>",
"    <li>",
"     Breathnach SM. Drug reactions. In: Rook's Textbook of Dermatology, 8th, Tony Burns, Stephen Breathnach, Neil Cox and Christopher Griffiths.  (Eds), Wiley-Blackwell, 2010. Vol IV.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9000/abstract/26\">",
"      Ozkaya E. Polysensitivity in fixed drug eruption due to a novel drug combination-independent lesions due to piroxicam and cotrimoxazole. Eur J Dermatol 2006; 16:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9000/abstract/27\">",
"      Walfish AE, Sapadin AN. Fixed drug eruption due to doxycycline and metronidazole. Cutis 2002; 69:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9000/abstract/28\">",
"      Mizukawa Y, Shiohara T. Fixed drug eruption presenting as erythema dyschromicum perstans: a flare without taking any medications. Dermatology 1998; 197:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9000/abstract/29\">",
"      Baird BJ, De Villez RL. Widespread bullous fixed drug eruption mimicking toxic epidermal necrolysis. Int J Dermatol 1988; 27:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9000/abstract/30\">",
"      Bandino JP, Wohltmann WE, Bray DW, Hoover AZ. Naproxen-induced generalized bullous fixed drug eruption. Dermatol Online J 2009; 15:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9000/abstract/31\">",
"      Ada S, Yilmaz S. Ciprofloxacin-induced generalized bullous fixed drug eruption. Indian J Dermatol Venereol Leprol 2008; 74:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9000/abstract/32\">",
"      Lipowicz S, Sekula P, Ingen-Housz-Oro S, et al. Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 2013; 168:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9000/abstract/33\">",
"      Mizukawa Y, Shiohara T. Nonpigmenting fixed drug eruption as a possible abortive variant of toxic epidermal necrolysis: immunohistochemical and serum cytokine analyses. Clin Exp Dermatol 2010; 35:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9000/abstract/34\">",
"      Baran R, Perrin C. Fixed-drug eruption presenting as an acute paronychia. Br J Dermatol 1991; 125:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9000/abstract/35\">",
"      Sigal-Nahum M, Konqui A, Gaulier A, Sigal S. Linear fixed drug eruption. Br J Dermatol 1988; 118:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9000/abstract/36\">",
"      Guin JD, Baker GF. Chronic fixed drug eruption caused by acetaminophen. Cutis 1988; 41:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9000/abstract/37\">",
"      Miah MA, Ahmed SS, Chowdhury SA, et al. Fixed drug eruptions due to cotrimoxazole. Mymensingh Med J 2008; 17:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9000/abstract/38\">",
"      Mahboob A, Haroon TS, Iqbal Z, et al. Fixed drug eruption: topical provocation and subsequent phenomena. J Coll Physicians Surg Pak 2006; 16:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9000/abstract/39\">",
"      Ozkaya-Bayazit E, Bayazit H, Ozarmagan G. Topical provocation in 27 cases of cotrimoxazole-induced fixed drug eruption. Contact Dermatitis 1999; 41:185.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15760 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-31C67D9254-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_50_9000=[""].join("\n");
var outline_f8_50_9000=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1633260\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1633148\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1633155\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1633162\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56452388\">",
"      Eliciting drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1633169\">",
"      Immunologic mechanisms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1512201\">",
"      HISTOPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1633176\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1633183\">",
"      CLINICAL VARIANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H54984555\">",
"      Erythema multiforme-like FDE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1511943\">",
"      Generalized FDE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1639622\">",
"      Generalized bullous FDE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1639685\">",
"      Nonpigmenting FDE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1511752\">",
"      Other variants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1633197\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1512454\">",
"      Clinical",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56451481\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1512461\">",
"      Provocation tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H56452116\">",
"      - Systemic provocation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1512468\">",
"      - Patch testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1633204\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1633253\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H54984425\">",
"      Drug withdrawal and avoidance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H54984433\">",
"      Symptomatic treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1633260\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/15760\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15760|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/57/13208\" title=\"picture 1A\">",
"      Fixed drug eruption dark skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/19/16691\" title=\"picture 1B\">",
"      Fixed drug eruption arm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/54/20321\" title=\"picture 1C\">",
"      Fixed drug hyperpigment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/6/22629\" title=\"picture 1D\">",
"      Fixed drug eruption with bulla",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/16/10499\" title=\"picture 1E\">",
"      Fixed drug eruption penis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/21/3414\" title=\"picture 2A\">",
"      Fixed drug eruption histo 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/5/25684\" title=\"picture 2B\">",
"      Fixed drug eruption histo 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/2/30759\" title=\"picture 3\">",
"      Fixed drug eruption histo 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/60/10178\" title=\"picture 4\">",
"      Fixed drug eruption before after",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/7/21619\" title=\"picture 5\">",
"      Bullous fixed drug eruption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/60/10179\" title=\"picture 6\">",
"      Erythema multiforme-like FDE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/17/29973\" title=\"picture 7\">",
"      Fixed drug eruption multiple",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/2/31778\" title=\"picture 8\">",
"      Erythema dyschromicum perstans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/56/27522\" title=\"picture 9\">",
"      Fixed drug eruption patch testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/53/19283\" title=\"picture 10\">",
"      Erythema multiforme target2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/14/13540\" title=\"picture 11\">",
"      Erythema multiforme acral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/48/25345\" title=\"picture 12\">",
"      Cutaneous changes of Stevens Johnson Syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/7/30836\" title=\"picture 13\">",
"      Mucosal changes in Stevens-Johnson syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/24/21892\" title=\"picture 14\">",
"      Bullous pemphigoid tense bullae 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/15/44279\" title=\"picture 15\">",
"      Bullous pemphigoid pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/47/43775\" title=\"picture 16\">",
"      Bullous pemphigoid DIF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/12/32963\" title=\"picture 17A\">",
"      Parapsoriasis large plaque",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/14/23781\" title=\"picture 17B\">",
"      Parapsoriasis dark skin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15760|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/56/39809\" title=\"table 1\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/62/24554?source=related_link\">",
"      An approach to the patient with drug allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=related_link\">",
"      Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=related_link\">",
"      Drug eruptions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24360?source=related_link\">",
"      Exanthematous (morbilliform) drug eruption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/48/3848?source=related_link\">",
"      Lichenoid drug eruption (drug-induced lichen planus)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/31/28150?source=related_link\">",
"      Patch testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37672?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of erythema multiforme",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6058?source=related_link\">",
"      Pruritus: Overview of management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33801?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_50_9001="High altitude PI";
var content_f8_50_9001=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F56882&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F56882&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    High altitude categories",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 676px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Doctors rank different altitudes as high, very high, or extreme based on the effects those altitudes have on the body. This graphic shows what can happen if you travel or climb to these altitudes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_50_9001=[""].join("\n");
var outline_f8_50_9001=null;
var title_f8_50_9002="Treatment and prognosis of Wilms tumor";
var content_f8_50_9002=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prognosis of Wilms tumor",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/50/9002/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/50/9002/contributors\">",
"     Murali Chintagumpala, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/50/9002/contributors\">",
"     Jodi A Muscal, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/50/9002/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/50/9002/contributors\">",
"     Alberto S Pappo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/50/9002/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/50/9002/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/50/9002/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wilms tumor is the most common renal malignancy in children [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/1\">",
"     1",
"    </a>",
"    ]. Survival rates have dramatically improved to a current five-year overall survival rate of 90 percent. This improvement in survival is due primarily to multimodal treatment (surgery, chemotherapy, and radiation) regimens based upon sequential clinical trials.",
"   </p>",
"   <p>",
"    The treatment and outcome of Wilms tumor will be reviewed here. The epidemiology, presentation, diagnosis, and staging of Wilms tumor are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/12/2249?source=see_link\">",
"     \"Presentation, diagnosis, and staging of Wilms tumor\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROGNOSTIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several prognostic factors at the time of initial diagnosis are associated with an increased risk of tumor recurrence or death, and include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tumor histology (anaplasia)",
"     </li>",
"     <li>",
"      Tumor stage",
"     </li>",
"     <li>",
"      Molecular and genetic markers",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of poor prognostic factor(s) leads to more aggressive initial therapeutic regimens, which are targeted to reduce the rates of tumor recurrence and death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Tumor histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of anaplasia is the most important predictor of adverse outcome in children with Wilms tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Anaplasia is defined as the presence of multipolar polypoid mitotic figures and marked nuclear enlargement with hyperchromasia, and it can be further classified as either focal (defined as tumors with anaplasia confined to one or a few discrete loci within the primary tumor, with no anaplasia or marked nuclear atypia elsewhere) or diffuse [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 632 patients from the National Wilms Tumor Study (NWTS) group with nonmetastatic disease at diagnosis, multivariate analysis demonstrated that anaplastic or sarcomatous histology was associated with increased rates of recurrence, metastases, and death [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Although diffuse anaplasia was only seen in 10 percent of patients, those with diffuse anaplastic tumor accounted for more than 60 percent of the deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/5\">",
"     5",
"    </a>",
"    ]. In the 165 cases with anaplastic histology, only three relapses and one death occurred among the 39 cases with focal anaplasia. In contrast, 22 of 23 children with stage IV diffuse anaplasia died of causes related to the tumor.",
"   </p>",
"   <p>",
"    In another report from the NWTS group, diffuse anaplasia was the most significant predictor of a shorter survival time after diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/6\">",
"     6",
"    </a>",
"    ]. a subsequent study has documented that patients with stage I disease with either focal or diffuse anaplasia have an inferior outcome when compared to stage I patients with favorable histology tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Tumor stage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Staging criteria for Wilms tumor are based on the anatomic extent of the tumor without consideration for genetic, histologic, or biologic markers [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/8\">",
"     8",
"    </a>",
"    ]. Higher stages (stages III through V) are associated with more extensive disease and a poorer outcome when compared to patients with lower stage disease (I and II) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/4,9-12\">",
"     4,9-12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Outcome'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There are two major staging systems currently in use (",
"    <a class=\"graphic graphic_table graphicRef78599 \" href=\"UTD.htm?14/4/14413\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Wilms Tumor Study staging &ndash; The NWTS surgical staging occurs",
"      <strong>",
"       prior",
"      </strong>",
"      to administration of chemotherapy and is used throughout the United States and Canada.",
"     </li>",
"     <li>",
"      International Society of Pediatric Oncology (SIOP) staging &ndash; The SIOP surgical staging occurs",
"      <strong>",
"       after",
"      </strong>",
"      four weeks of chemotherapy and is used extensively in Europe.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both staging criteria are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/12/2249?source=see_link&amp;anchor=H16#H16\">",
"     \"Presentation, diagnosis, and staging of Wilms tumor\", section on 'Staging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, children less than 24 months of age generally had lower relapse rates than older patients, which resulted in a better clinical outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/13\">",
"     13",
"    </a>",
"    ]. With improved therapeutic interventions, the effect of age as a prognostic factor has been reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/4,14\">",
"     4,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adults with Wilms tumor have the same survival rate as children with similar tumor histology and stage when treated with the same therapeutic regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. However, the rate of treatment-related toxicity appears to be higher in adult patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Biologic markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several biological markers appear to be predictive of outcome.",
"   </p>",
"   <p>",
"    The most promising of these is the loss of heterozygosity (LOH) at chromosome 16q, 1p, 11p15 in tumor cells [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Patients with these molecular markers have increased rates of relapse and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/18-22\">",
"     18-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon these findings, ongoing trials are assessing the presence of these markers in the staging and assignment of risk-directed therapy in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition, ongoing research is focused on the use of gene expression profiles to predict prognosis and guide therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. Ultimately, gene expression profiles may aid in patient stratification and assignment to different treatment regimens especially identifying patients who may require surgery only [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most children with newly diagnosed Wilms tumor are treated on research protocols, and risk-based therapy is assigned based on results of the initial staging, histological, and molecular studies. These regimens conducted by cooperative groups incorporate multimodal therapy (surgery, chemotherapy, and radiation), and have resulted in dramatic improvements in outcome in these children with overall five-year survival rates of 90 percent. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Outcome'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H2\">",
"     'Prognostic factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The two major research groups that care for the largest number of patients with Wilms tumor are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Wilms Tumor Study (NWTS) group &ndash; The NWTS group was established in 1969 and includes almost all of the pediatric oncology centers in the United States and Canada. The NWTS has been incorporated into the Children's Oncology Group (COG), which now conducts all trials in children with Wilms tumor in North America. Our institution is a member of the COG group.",
"     </li>",
"     <li>",
"      International Society of Pediatric Oncology (SIOP) &ndash; The SIOP group was established in the early 1970s. It primarily includes European pediatric oncology centers with additional centers located in Asia and Africa.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children who are suspected of having Wilms tumor should be referred to a pediatric cancer center for evaluation and treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Unilateral renal involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The NWTS and SIOP differ in their management of unilateral Wilms tumor (stages I through IV Wilms tumor), specifically regarding the timing of chemotherapy relative to surgical excision [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/20\">",
"     20",
"    </a>",
"    ]. NWTS encourages the use of primary surgical resection",
"    <strong>",
"     prior",
"    </strong>",
"    to chemotherapy administration. In contrast, SIOP protocols primarily use an initial course of chemotherapy followed by surgical resection and staging four weeks",
"    <strong>",
"     after",
"    </strong>",
"    the administration of chemotherapy. Both treatment approaches have excellent and comparable clinical outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Outcome'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     National Wilms Tumor Study",
"    </span>",
"    &nbsp;&mdash;&nbsp;The NWTS group has conducted clinical trials since 1969 based upon primary surgical resection as initial treatment for children with unilateral Wilms tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/3,4,10,26-30\">",
"     3,4,10,26-30",
"    </a>",
"    ]. Adjuvant chemotherapy is administered after surgery. The choice of chemotherapeutic agents and the length of therapy (18 versus 24 weeks) are dependent upon the tumor histology and stage (",
"    <a class=\"graphic graphic_table graphicRef78599 \" href=\"UTD.htm?14/4/14413\">",
"     table 1",
"    </a>",
"    ). Radiation therapy is used in patients with stage III or IV tumors. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Tumor histology'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H4\">",
"     'Tumor stage'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Because our institution is a member of the",
"    <span class=\"nowrap\">",
"     NWTS/COG",
"    </span>",
"    group, we treat patients using the",
"    <span class=\"nowrap\">",
"     NWTS/COG",
"    </span>",
"    protocols or use these protocols as guidelines for therapy (",
"    <a class=\"graphic graphic_table graphicRef64794 \" href=\"UTD.htm?24/54/25452\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/8\">",
"     8",
"    </a>",
"    ]. We currently are enrolling patients based upon the COG protocols for treatment of all stages of Wilms tumor with both favorable and unfavorable histologic features.",
"   </p>",
"   <p>",
"    Our approach for treatment of Wilms tumor is based upon the tumor stage and the COG protocols as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stages I and II with favorable histology &ndash; Primary surgical resection is followed by 19 weeks of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/12/33993?source=see_link\">",
"       vincristine",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/61/8150?source=see_link\">",
"       dactinomycin",
"      </a>",
"      . No radiation therapy is required. Primary resection alone resulted in a higher relapse rate than the combination of surgical excision and chemotherapy and is not currently recommended [",
"      <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients less than two years of age with stage 1 favorable histology and a tumor that weighs less than 550 grams may not require adjuvant chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In a trial by the NWTS, children less than two years of age with small (&lt;550 g) Stage I favorable histology were randomly assigned to either surgery alone or surgery followed by adjunctive chemotherapy (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/12/33993?source=see_link\">",
"       vincristine",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/61/8150?source=see_link\">",
"       dactinomycin",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/33\">",
"       33",
"      </a>",
"      ]. Of the 77 patients initially treated with only surgery, 21 were recalled and received the adjunctive protocol chemotherapy after the experimental arm of the study was closed (median time after enrollment 0.54 years). The estimated five-year event free survival (EFS) rate was lower in those initially treated only with surgery compared to those treated with a combination of surgery and adjunctive therapy (84 versus 97 percent). Of the 11 treatment failures in the surgery group, one occurred after the patient was recalled and received adjunctive therapy. The other 10 patients received chemotherapy and radiation therapy based on protocols for specific recurrent tumor sites. One death was observed in each group, resulting in no difference in mortality. The authors concluded that although the EFS was lower in the surgery only group, the overall mortality rate did not differ, and a majority of the infants in the surgery only group were spared the adverse effects of chemotherapy. Continued evaluation of this trial (long-term outcome) and other research efforts are ongoing in the Children's Oncology Group to determine whether or not surgery alone in this group of patients with low-risk Wilms tumor is the initial optimal therapy.",
"     </li>",
"     <li>",
"      In ongoing COG studies, treatment options are being evaluated in all other stage I patients and all stage II patients. Those with favorable histology who do not have loss of heterozygosity (LOH, both 1p and 16q) will be treated with two drugs:",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/12/33993?source=see_link\">",
"       vincristine",
"      </a>",
"      and actinomycin D. When there is LOH of both 1p and 16g in patients with stage I disease who are either equal to or greater than two years of age or their tumor weighs more than or equal to 550 grams, the treatment will consist of three drugs with the addition of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/14/20711?source=see_link\">",
"       doxorubicin",
"      </a>",
"      to actinomycin D and vincristine. Similarly any patient with stage II disease with LOH of 1p and 16q will receive three drugs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with stage",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      disease and anaplastic histology have a poorer prognosis and the additional use of chemotherapy and radiation therapy is currently being evaluated. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Anaplastic histology'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Stage III &ndash; Primary surgical resection is followed by 24 weeks of triple drug chemotherapy of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/12/33993?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/61/8150?source=see_link\">",
"       dactinomycin",
"      </a>",
"      , and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/14/20711?source=see_link\">",
"       doxorubicin",
"      </a>",
"      . Radiation therapy (dose of 10.8 Gy) based on lymph node involvement or the extent of the peritoneal contamination is administered to the affected flank, hemi-abdomen, or complete abdomen. In ongoing COG studies, patients with stage III disease with LOH for both 1p and 16q will receive",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/17/41240?source=see_link\">",
"       etoposide",
"      </a>",
"      in addition to the standard triple drug therapy",
"     </li>",
"     <li>",
"      Stage IV &ndash; Primary surgical resection is followed by 24 weeks of triple drug chemotherapy of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/12/33993?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/61/8150?source=see_link\">",
"       dactinomycin",
"      </a>",
"      , and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/14/20711?source=see_link\">",
"       doxorubicin",
"      </a>",
"      . In an ongoing COG study, radiation therapy (dose of 12 Gy) is administered to the whole lung field only if the lung metastases do not completely respond after six weeks of chemotherapy. If the lung metastases are completely resected prior to enrollment, then whole lung radiation will start at week one. In patients with evidence of spread of disease to the regional lymph nodes in the hilum",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      para-aortic nodes, radiation therapy (dose of 10.8 Gy) is administered to the loco-regional area including the appropriate half of the abdomen as indicated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     International Society of Pediatric Oncology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The SIOP regimens for treatment of stages I through IV Wilms tumor with favorable histologic features (",
"    <a class=\"graphic graphic_table graphicRef78599 \" href=\"UTD.htm?14/4/14413\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/8\">",
"     8",
"    </a>",
"    ] are based upon clinical trials conducted from 1971 to 2000 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/34-38\">",
"     34-38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pre-operative chemotherapy with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/12/33993?source=see_link\">",
"     vincristine",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/61/8150?source=see_link\">",
"     dactinomycin",
"    </a>",
"    are administered to patients with renal tumors for four weeks prior to surgery. However, if there is evidence of metastatic disease beyond the abdominal-peritoneal region (eg, lung metastases), triple drug chemotherapy (vincristine, dactinomycin, and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/14/20711?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ) is given for six weeks preoperatively. Following preoperative chemotherapy, surgical excision and staging are performed.",
"   </p>",
"   <p>",
"    In some centers, biopsies are used to make a histologic diagnosis prior to the initiation of chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/39\">",
"     39",
"    </a>",
"    ]. However, tumor biopsy may result in the introduction of tumor cells within the abdominal cavity, which increases the tumor stage to stage III resulting in a more intense postoperative regimen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/12/2249?source=see_link&amp;anchor=H16#H16\">",
"     \"Presentation, diagnosis, and staging of Wilms tumor\", section on 'Staging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Postoperative SIOP regimens are based upon tumor staging as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage I &ndash; Postoperative chemotherapy with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/12/33993?source=see_link\">",
"       vincristine",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/61/8150?source=see_link\">",
"       dactinomycin",
"      </a>",
"      is administered for four weeks. No radiation therapy is given.",
"     </li>",
"     <li>",
"      Stage II &ndash; Postoperative chemotherapy with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/12/33993?source=see_link\">",
"       vincristine",
"      </a>",
"      , actinomycin, and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/14/20711?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , is administered for 27 weeks. If there is tumor involvement of the regional lymph nodes, radiation therapy (dose of 15 Gy) is given.",
"     </li>",
"     <li>",
"      Stage III &ndash; Postoperative chemotherapy with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/12/33993?source=see_link\">",
"       vincristine",
"      </a>",
"      , actinomycin, and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/14/20711?source=see_link\">",
"       doxorubicin",
"      </a>",
"      is administered for 27 weeks. Radiation therapy (dose of 15 Gy) is given.",
"     </li>",
"     <li>",
"      Stage IV &ndash; Initial postoperative chemotherapy with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/12/33993?source=see_link\">",
"       vincristine",
"      </a>",
"      , actinomycin, and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/14/20711?source=see_link\">",
"       doxorubicin",
"      </a>",
"      is given. After nine weeks, if complete remission is achieved, the same chemotherapeutic regimen is administered for a total course of 27 weeks. If complete remission is not achieved after nine weeks, chemotherapy is intensified with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/33/11800?source=see_link\">",
"       ifosfamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/10/43174?source=see_link\">",
"       carboplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/17/41240?source=see_link\">",
"       etoposide",
"      </a>",
"      , and doxorubicin for an additional 34 weeks. If lung lesions persist after 9 weeks of initial chemotherapy, radiation therapy (dose of 12 Gy) is administered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Comparison of approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the NWTS and SIOP regimens differ in the timing of chemotherapy relative to surgical excision, they have comparable current five-year overall survival rates of 90 percent. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Outcome'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The two regimens have the following advantages and disadvantages:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preoperative chemotherapy (SIOP regimen) usually reduces tumor volume, and may make surgical excision easier, thus decreasing the likelihood of tumor spillage [",
"      <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/40\">",
"       40",
"      </a>",
"      ]. This appears to reduce the potential need for local radiation due to spillage of tumor cells [",
"      <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the SIOP approach, patients with benign renal tumors may receive preoperative chemotherapy. This was illustrated in several SIOP trials that reported 1.5 percent of patients who received chemotherapy had benign tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/37,38\">",
"       37,38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Initial surgical excision (NWTS regimen) allows an accurate assessment of the histologic diagnosis and tumor extent. It prevents patients with benign tumors from receiving unnecessary chemotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a study from the United Kingdom Children's Cancer Study Group, patients with newly diagnosed potentially resected renal tumors were randomly selected to undergo immediate nephrectomy, or percutaneous renal biopsy, followed by chemotherapy and then nephrectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/42\">",
"     42",
"    </a>",
"    ]. There was no difference between the two groups in five-year event-free survival. Further clinical trials comparing the two approaches are required to determine the most efficacious and safe regimen in the management of Wilms tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Bilateral renal involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although only 7 percent patients with Wilms tumors present with stage V disease (bilateral renal involvement), their care is challenging as the therapeutic goal is to adequately treat the bilateral tumor loci while trying to preserve renal function.",
"   </p>",
"   <p>",
"    Historically, the management of patients with bilateral disease included initial nephrectomy of the more involved side combined with partial nephrectomy or excisional resection of the lesion in the contralateral kidney (initial surgical excision). In these patients, recurrent tumor and subsequent nephrectomy of the remaining kidney occurred and accounted for the majority of cases of end-stage renal failure in patients with Wilms tumors. This was illustrated in a study of 39 patients with ESRD from the NWTS group [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/43\">",
"     43",
"    </a>",
"    ]. Renal failure was caused by subsequent nephrectomy of the remaining renal tissue for persistent or recurrent tumor in 24 patients who had bilateral Wilms tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Late effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In retrospective studies of children with stage V disease conducted by NWTS, renal parenchymal-sparing resection (tumor resection following preoperative chemotherapy) have comparable overall patient survival to those with initial surgical excision [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. This was illustrated in a review of 188 children with bilateral disease enrolled in the NWTS-4 who underwent renal parenchymal-sparing resection. Although pre-resection chemotherapy was recommended, in 83 patients, primary surgical interventions was performed including complete nephrectomy in 48 patients, 31",
"    <span class=\"nowrap\">",
"     partial/wedge",
"    </span>",
"    resections, and enucleations in 8 patients. No initial surgery was performed in 43 patients, and 5 kidneys in three patients were not coded. Relapse or progression of disease occurred in 54 patients, and ESRD in 23 children including 6 with bilateral nephrectomies. The eight year event free survival and patient survival were 74 and 89 percent in patients with favorable histology, and 40 and 45 percent in those with unfavorable histology. &nbsp;",
"   </p>",
"   <p>",
"    In a retrospective study from a single center, 10 of 12 patients with stage V disease underwent bilateral nephron-sparing resection [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/47\">",
"     47",
"    </a>",
"    ]. The overall survival rate was 83 percent at a mean follow-up of 3.9 years, and 9 of 10 surviving patients had no evidence of disease. The two patients who died had bilateral diffuse anaplastic histology. Long-term complications included local tumor recurrence in two patients, intestinal obstruction in two, ureteropelvic junction obstruction in one, and renal failure in one patient.",
"   </p>",
"   <p>",
"    Therefore, renal parenchymal-sparing resection appears to have some promise in reducing the number of children with bilateral disease who require dialysis and eventual renal transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/44\">",
"     44",
"    </a>",
"    ]. This requires confirmation by prospective long-term outcome studies.",
"   </p>",
"   <p>",
"    The current treatment protocol in COG for children with bilateral Wilms tumor, which we use at our institution, evaluates the efficacy of more intensive chemotherapy at the time of diagnosis in facilitating early nephron-sparing surgery and establishing early definitive histopathologic diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/8,46,48,49\">",
"     8,46,48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the current trial, preoperative chemotherapy consists of a six week regimen of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/12/33993?source=see_link\">",
"       vincristine",
"      </a>",
"      , actinomycin, and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/14/20711?source=see_link\">",
"       doxorubicin",
"      </a>",
"      . One of the goals of the this protocol is to determine if triple drug chemotherapy is more effective than two drug regimen (vincristine and actinomycin) in decreasing the tumor size and allowing better preservation of renal parenchyma [",
"      <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/46,49\">",
"       46,49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Postoperative chemotherapy and radiotherapy is administered based upon the histopathology findings of the resected tumor and the presence of tumor in the lymph nodes or the peritoneal cavity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Anaplastic histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with diffuse anaplastic tumor have a poorer outcome. As a result, trials using more intensive therapy (eg, addition of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/17/41240?source=see_link\">",
"     etoposide",
"    </a>",
"    ) have been conducted in patients with anaplastic Wilms tumor. Despite the more aggressive intervention, the 4-year event-free survival (EFS) rate is only about 55 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/50\">",
"     50",
"    </a>",
"    ]. Future clinical trials are planned in the hopes of finding a more effective regimen that will improve the EFS of patients with diffuse anaplastic Wilms tumor. In particular, new treatment protocols include flank radiation therapy for patients with stage I and II with focal or diffuse anaplastic histology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Lung metastases",
"    </span>",
"   </p>",
"   <p>",
"    Chest imaging for patients with Wilms tumor is an area of controversy. Even when treatment protocols only require chest radiography (CXR), computed tomography (CT) is generally used to detect pulmonary metastatic disease as it remains uncertain what the optimal approach is for detecting lung metastases. Although CT is more sensitive in detecting pulmonary disease, it is unclear whether diagnosing these lesions improves outcome as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A SIOP retrospective study of 103 patients did not find a benefit in routine chest CT at diagnosis for patients with unilateral Wilms tumor [",
"      <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a COG retrospective study of 417 patients with unilateral favorable histology Wilms tumor and lung metastases, 231 lesions were detected by chest radiography and 186 by CT only [",
"      <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/52\">",
"       52",
"      </a>",
"      ]. Of the 186 patients with lesions only detected by CT scan, those who received",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/14/20711?source=see_link\">",
"       doxorubicin",
"      </a>",
"      in addition to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/12/33993?source=see_link\">",
"       vincristine",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/61/8150?source=see_link\">",
"       dactinomycin",
"      </a>",
"      with or without lung radiation had improved five-year EFS than those who received only two drugs (80 versus 56 percent). These results suggest that the more intensive therapy for patients with lung metastases detected only by CT scan improved patient outcome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because optimal management of patients with lung metastases remains uncertain, various approaches are currently being studied as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In SIOP protocols, chest radiography is used to evaluate the lung metastases response to therapy. If lung nodules disappear from subsequent chest radiographs after a few courses of chemotherapy, radiation to lungs is not given. In one study of 36 patients with favorable histology from six centers treated with this regimen, the four-year event-free survival (EFS) rate was 83 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study from the United Kingdom Children's Cancer Study Group reported a six-year survival rate of 65 percent in patients with lung metastases and favorable tumor histology who did not receive lung irradiation [",
"      <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/54\">",
"       54",
"      </a>",
"      ]. A subsequent study from this group showed that outcome may be compromised if pulmonary radiation is not performed in patients with lung metastases [",
"      <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/55\">",
"       55",
"      </a>",
"      ]. Of 102 eligible patients, 72 received radiotherapy to the lungs and 30 did not receive radiotherapy. At a median follow-up of 9.3 years, the event-free survival rate was better in patients who received pulmonary radiation (79 versus 53 percent).",
"     </li>",
"     <li>",
"      A COG trial is enrolling patients in an attempt to identify a subset of patients with lung metastases who may not require pulmonary radiation therapy. This study will address the question of whether radiation is of additional benefit in patients with lung metastases, which completely resolve following the initial six weeks of chemotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110256064\">",
"    <span class=\"h2\">",
"     Survival rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall five-year survival rates for Wilms tumor has steadily improved from 20 percent in the late 1960s to 90 percent in the most recent clinical trials from both the National Wilms Tumor Study (NWTS)",
"    <span class=\"nowrap\">",
"     /",
"    </span>",
"    Children's Oncology Group (COG) and International Society of Pediatric Oncology (SIOP) groups [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/8,28,38\">",
"     8,28,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a review of 6185 patients enrolled in the NWTS between 1969 and 1995, the overall survival rate was 84 percent through 2002 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/56\">",
"     56",
"    </a>",
"    ]. The following causes of death, including their relative frequency were observed:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tumor -related &ndash; 86 percent",
"     </li>",
"     <li>",
"      Late effects of therapy &ndash; 9 percent",
"     </li>",
"     <li>",
"      Nontreatment or nondisease-related &ndash; 5 percent",
"     </li>",
"     <li>",
"      Unknown &ndash; 1 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ninety-one percent of deaths occurred early within the first five years of diagnosis (n = 819) and were primarily due to the original tumor (94 percent). In contrast, most of the causes of the 159 late deaths were evenly distributed between the late effects of therapy (39 percent) and tumor-related mortality (40 percent).",
"   </p>",
"   <p>",
"    Event-free survival (EFS) rates vary among individuals and are dependent upon the tumor histology, stage, and size, and the age of the patient at diagnosis. This is illustrated by the following findings from the NWTS trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who are under two years of age with small stage I favorable-histology tumor (less than 550 g in weight) have the best prognosis with four year event-free survival (EFS) rates of 93 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with stage II or III favorable-histology tumor have reported eight-year EFS rates of 84 to 90 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/8,57\">",
"       8,57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with diffuse anaplastic tumor have the poorest prognosis. In a trial of patients with stage II through IV diffuse anaplastic tumor, a regimen of four-drug chemotherapy (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/12/33993?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/61/8150?source=see_link\">",
"       dactinomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/14/20711?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,) and abdominal radiation resulted in four-year EFS rates of 54 percent versus 27 percent in patients who received the same regimen but without cyclophosphamide, [",
"      <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/50\">",
"       50",
"      </a>",
"      ]. Similar poor outcome was reported in a trial from SIOP of 21 patients with diffuse anaplastic Wilms tumor with a five-year EFS rate of 38 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The four-year patient survival rate for patients with stage V (bilateral) Wilms tumor with favorable histology is approximately 82 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/45\">",
"       45",
"      </a>",
"      ] and 70 percent at 10 years after diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/12\">",
"       12",
"      </a>",
"      ]. However, patients with diffuse anaplasia in one kidney have a lower survival rate [",
"      <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Tumor recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 15 percent of children with favorable histology Wilms tumor, and 50 percent of those with anaplastic features develop recurrent disease. The majority of recurrences occur within the first two years of therapy. Recurrences most often involve the lung.",
"   </p>",
"   <p>",
"    Approximately 1 percent of children develop tumor in the contralateral kidney six years after the initial diagnosis of Wilms tumor, with 90 percent occurring within the first two years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/10,28\">",
"     10,28",
"    </a>",
"    ]. The presence of nephrogenic rests (foci of persistent metanephric cells) places a child at increased risk for tumor recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/12/2249?source=see_link&amp;anchor=H8#H8\">",
"     \"Presentation, diagnosis, and staging of Wilms tumor\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although survival rates have improved with salvage therapy, patients who have recurrence of their tumor have post-relapse three-year and five-year survival rates of 50 to 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/61,62\">",
"     61,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with recurrent tumor, the following prognostic factors are associated with favorable response to salvage therapy and improved outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/8,62,63\">",
"     8,62,63",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Relapse occurs more than 12 months after initial diagnosis",
"     </li>",
"     <li>",
"      Favorable histology of the initial tumor",
"     </li>",
"     <li>",
"      Low tumor stage of initial disease",
"     </li>",
"     <li>",
"      Initial treatment with only",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/61/8150?source=see_link\">",
"       dactinomycin",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/12/33993?source=see_link\">",
"       vincristine",
"      </a>",
"     </li>",
"     <li>",
"      Few pulmonary nodules",
"     </li>",
"     <li>",
"      No previous radiation to tumor bed",
"     </li>",
"     <li>",
"      Complete resection of original tumor",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High telomerase RNA expression [",
"      <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/64\">",
"       64",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the optimal salvage therapy regimen for patients with Wilms tumor has not yet been established, multi-agent regimens with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/33/11800?source=see_link\">",
"     ifosfamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/10/43174?source=see_link\">",
"     carboplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/17/41240?source=see_link\">",
"     etoposide",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/8/34949?source=see_link\">",
"     cisplatin",
"    </a>",
"    have been used to varying degrees of success [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/61,65-76\">",
"     61,65-76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High-dose chemotherapy with stem cell rescue has been suggested as an option in patients with recurrent tumor, especially in those with adverse prognostic indicators. However, the efficacy of this approach remains unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Early complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early complications are generally related to therapy and include adverse effects of chemotherapeutic drugs and surgical complications such as bowel obstruction, hemorrhage, and wound infection [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Late effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survivors are at increased risk for long-term sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/78\">",
"     78",
"    </a>",
"    ]. Late adverse effects are primarily dependent upon the type and intensity of therapy used to treat patients. Patients who received more intense chemotherapy and radiation therapy are more likely to have late complications. These include renal impairment, cardiotoxicity, hepatotoxicity, orthopedic, growth, and pulmonary problems, infertility, and secondary malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renal impairment &ndash; Renal impairment may be caused by surgical loss of renal parenchyma, and renal injury from chemotherapy and radiation therapy. Patients with bilateral renal involvement are at increased risk for renal impairment [",
"      <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/12,43,80\">",
"       12,43,80",
"      </a>",
"      ], especially if they also received radiation therapy. This was illustrated from a study from the NWTS group of 81 patients with stage V tumor who received radiation therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/81\">",
"       81",
"      </a>",
"      ]. A third of patients had elevated serum creatinine concentrations, 18 patients had moderate renal insufficiency, and 10 had severe renal insufficiency.",
"      <br/>",
"      <br/>",
"      End-stage renal disease requiring renal replacement therapy is most frequently due to bilateral Wilms tumor. However, other causes of ESRD include Denys-Drash syndrome, radiation nephritis, or WAGR syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/82-84\">",
"       82-84",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/12/2249?source=see_link&amp;anchor=H4#H4\">",
"       \"Presentation, diagnosis, and staging of Wilms tumor\", section on 'WAGR syndrome'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/12/2249?source=see_link&amp;anchor=H5#H5\">",
"       \"Presentation, diagnosis, and staging of Wilms tumor\", section on 'Denys-Drash syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiotoxicity &ndash; Treatment with anthracyclines (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/14/20711?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ) may cause cardiovascular complications including heart failure and increased left ventricular afterload [",
"      <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/85,86\">",
"       85,86",
"      </a>",
"      ]. Risk of developing cardiac abnormalities is dependent upon the cumulative dose and the dose-intensity used. In a report of 97 patients with Wilms tumor who received doxorubicin (mean cumulative dose 303",
"      <span class=\"nowrap\">",
"       mg/m2),",
"      </span>",
"      25 percent of patients had evidence of increased left ventricular afterload documented by echocardiography [",
"      <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/86\">",
"       86",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link\">",
"       \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hepatotoxicity &ndash; Chemotherapeutic agents (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/12/33993?source=see_link\">",
"       vincristine",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/61/8150?source=see_link\">",
"       dactinomycin",
"      </a>",
"      ) and hepatic irradiation may damage the liver [",
"      <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/87,88\">",
"       87,88",
"      </a>",
"      ]. The liver damage from dactinomycin appears to be dose-related as illustrated by the varying incidence of hepatotoxicity (2.8 to 14.3 percent) in patients who received different doses and schedules of dactinomycin [",
"      <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/88\">",
"       88",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fertility &ndash; Patients with Wilms tumor generally do not have infertility problems. However, females who received high doses of abdominal radiation have higher rates of pregnancy complications, perinatal mortality, and low birth weight babies [",
"      <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/89-91\">",
"       89-91",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Second malignancies &ndash; Patients with Wilms tumors are at increased risk for developing second malignancies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In a report from the NWTS group that reviewed the late outcome of 5278 patients treated between 1969 and 1991, there were 43 cases of second neoplasms [",
"      <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/92\">",
"       92",
"      </a>",
"      ]. The overall risk was estimated to be 1.6 percent at 15 years, and the highest risk was among patients who received radiation therapy and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/14/20711?source=see_link\">",
"       doxorubicin",
"      </a>",
"      . All reported second solid tumors occurred within the radiation field and were detected at a mean of 16.1 years post-therapy for the original Wilms tumor.",
"     </li>",
"     <li>",
"      In another study of a large international cohort of patients diagnosed with Wilms tumor before 15 years of age during 1960 to 2004, 174 solid tumors and 28 leukemias were detected in 13,357 patients after observation through 2005 [",
"      <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/93\">",
"       93",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a report from the Childhood Cancer Survivor Study, 3 percent of survivors developed second malignancies 25 years after initial diagnosis of Wilms tumor [",
"      <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other adverse effects from radiation &ndash; Other complications resulting from radiation therapy include muscle atrophy, short stature, and scoliosis. Children who receive 10 Gy or more at an age younger than 1 year are at most likely to have growth (height) impairment. Stature loss is due to the extension of standard flank radiation over the spinal column [",
"      <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/94,95\">",
"       94,95",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Radiation to the chest for lung metastases may result in thyroid disease and damage mammary tissue in young patients. Higher doses of radiation to the liver are associated with increased risk of portal hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/96\">",
"       96",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with Wilms tumor should be examined on a regular basis by a clinician who is familiar with the natural history of the disease and the complications of therapy. Follow-up care includes ongoing surveillance for tumor recurrence and late treatment-related complications.",
"   </p>",
"   <p>",
"    The primary care provider (PCP) can often provide routine care with coordinated scheduled visits to the oncologist, especially if the family lives some distance from the oncology treatment center. Long-term follow-up guidelines for children who have received treatment for cancer in childhood are available at the Children's Oncology Group web site,",
"    <a class=\"external\" href=\"file://www.survivorshipguidelines.org/\">",
"     www.survivorshipguidelines.org",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Screening for tumor recurrence",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23821332\">",
"    <span class=\"h3\">",
"     Pulmonary surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lung is the most frequent first site of recurrence. Although, tumor recurrence is best detected by lung computed tomography (CT), this modality is associated with increased radiation exposure compared to ultrasonography or chest radiography. As a result, there is no consensus regarding the best modality for screening or the frequency of screening.",
"   </p>",
"   <p>",
"    Ongoing pulmonary surveillance usually alternates chest radiography and abdominal ultrasound with chest, abdomen, and pelvic CT. Imaging studies are performed every six to eight weeks during therapy, then every three months for two years, and followed by every six months for an additional two years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23821339\">",
"    <span class=\"h3\">",
"     Abdominal surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal ultrasonography is performed to detect tumor recurrence in residual kidney tissue or another abdominal location. Abdominal ultrasound can detect early infradiaphragmatic relapses, which may be seen in patients with stage II and III tumor. The frequency of ultrasonography is dependent on whether nephrogenic rests (foci of persistent metanephric cells) were identified in the kidney(s) at the time of initial tumor diagnosis. Patients with nephrogenic rests are at increased risk for relapse. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Tumor recurrence'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/12/2249?source=see_link&amp;anchor=H8#H8\">",
"     \"Presentation, diagnosis, and staging of Wilms tumor\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At our institution, we utilize the following schedule for abdominal ultrasonography [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/48\">",
"     48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with nephrogenic rests or those with tumor-predisposing syndromes (WAGR, Denys-Drash, or Beckwith-Wiedemann syndromes), exams are performed every three months until the child is eight years old.",
"     </li>",
"     <li>",
"      In patients without nephrogenic rests or tumor-predisposing syndromes, exams are performed every three months for two years and then every six months for an additional two years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Screening for therapy-related complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening for late complications is based upon the expected likelihood of adverse events related to the therapeutic regimens used. Many of these complications, as previously described, can be detected by history, physical examination, assessment of serum creatinine and urinalysis, and echocardiogram. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Late effects'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In addition, patients with stage IV are at risk for late effects of radiation therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who received bone radiation therapy should be monitored for radiation-associated second neoplasm with annual bone radiographs of the irradiated bones until full growth is attained and then every five years.",
"     </li>",
"     <li>",
"      Patients who received chest radiation therapy should have thyroid functions tests obtained yearly for at least five years for surveillance of hypothyroidism. These patients are also at risk for pulmonary function abnormalities, and pulmonary function studies should be considered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     FUTURE DIRECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the current overall survival rate of 90 percent in children with Wilms tumor, future research will shift towards maximizing cure while minimizing treatment-related toxicities. Future trials will also study the role of biological markers in identifying patients with a poorer prognosis and, perhaps, guiding therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/50/9002/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Biologic markers'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survival rates have dramatically improved in patients with Wilms tumors to the current five-year overall survival rate of 90 percent.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      This improved outcome is a result of clinical trials based upon multimodal therapy (surgery, chemotherapy, and radiation therapy), which were primarily conducted by two cooperative groups, the National Wilms Tumor Study (NWTS) group and the International Society of Pediatric Oncology (SIOP). The NWTS group has been incorporated into the Children's Oncology Group (COG).",
"     </li>",
"     <li>",
"      Both the",
"      <span class=\"nowrap\">",
"       NWTS/COG",
"      </span>",
"      and SIOP groups use risk-directed therapeutic regimens that are based upon prognostic factors, particularly histologic documentation of diffuse anaplasia (unfavorable histology) and advanced tumor stage (eg, tumor stages III through V), (",
"      <a class=\"graphic graphic_table graphicRef78599 \" href=\"UTD.htm?14/4/14413\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef64794 \" href=\"UTD.htm?24/54/25452\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prognostic factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with unilateral Wilms tumor (stages I through IV), we recommend that patients be treated with multimodal therapeutic regimens that include surgical excision and chemotherapy, and the addition of radiation therapy for stages III and IV tumor (",
"      <a class=\"graphic graphic_table graphicRef64794 \" href=\"UTD.htm?24/54/25452\">",
"       table 2",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Currently, ongoing protocols are evaluating whether the addition of radiation therapy is beneficial to patients with stage I and II tumors with focal or diffuse anaplastic histology. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Management'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Because our institution is a member of the COG group, we treat patients with unilateral Wilms tumor with initial surgical excision followed by chemotherapy. An alternate approach (used by the SIOP group) is to treat patients preoperatively with chemotherapy prior to surgical excision. In both approaches, radiation therapy is administered to patients with stage III or IV tumor. Patients treated by either approach have excellent and comparable clinical outcomes",
"     </li>",
"     <li>",
"      For patients with bilateral Wilms tumor (stage V), we suggest preoperative chemotherapy followed by renal parenchymal-sparing resection rather than initial surgical excision (unilateral nephrectomy of the more involved side and partial nephrectomy of the contralateral kidney) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The two approaches have comparable overall patient survival rates and the renal parenchymal-sparing resection may reduce the number of children with end stage renal failure. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Bilateral renal involvement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the overall five-year survival rates is 90 percent in the most recent clinical trials from both the NWTS and SIOP groups, event-free survival (EFS) rates vary among individuals and are primarily dependent upon tumor histology and stage. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of tumor recurrence is dependent tumor histology. Recurrent disease develops in 15 percent of children with favorable histology Wilms tumor and 50 percent of those with anaplastic features. Although salvage therapy has improved survival rates, the post-relapse three-year and five-year survival rates are only 50 to 60 percent. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Tumor recurrence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Long-term complications are related to the type and intensity of the treatment regimen. Patients with diffuse anaplastic tumors or higher stage tumors receive more aggressive chemotherapy and radiation therapy, and are at greater risk for both early and late adverse effects. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Long-term follow-up is necessary for survivors of Wilms tumor for ongoing surveillance for tumor recurrence and late treatment-related complications. This includes scheduled imaging of the chest (chest computed tomography [CT] or chest radiography) and abdomen (abdominal ultrasonography or CT). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/1\">",
"      Grovas A, Fremgen A, Rauck A, et al. The National Cancer Data Base report on patterns of childhood cancers in the United States. Cancer 1997; 80:2321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/2\">",
"      Zuppan CW, Beckwith JB, Luckey DW. Anaplasia in unilateral Wilms' tumor: a report from the National Wilms' Tumor Study Pathology Center. Hum Pathol 1988; 19:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/3\">",
"      D'Angio GJ, Evans A, Breslow N, et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer 1981; 47:2302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/4\">",
"      Breslow N, Churchill G, Beckwith JB, et al. Prognosis for Wilms' tumor patients with nonmetastatic disease at diagnosis--results of the second National Wilms' Tumor Study. J Clin Oncol 1985; 3:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/5\">",
"      Faria P, Beckwith JB, Mishra K, et al. Focal versus diffuse anaplasia in Wilms tumor--new definitions with prognostic significance: a report from the National Wilms Tumor Study Group. Am J Surg Pathol 1996; 20:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/6\">",
"      Bonadio JF, Storer B, Norkool P, et al. Anaplastic Wilms' tumor: clinical and pathologic studies. J Clin Oncol 1985; 3:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/7\">",
"      Dome JS, Cotton CA, Perlman EJ, et al. Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study. J Clin Oncol 2006; 24:2352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/8\">",
"      Metzger ML, Dome JS. Current therapy for Wilms' tumor. Oncologist 2005; 10:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/9\">",
"      Green DM, Breslow NE, Beckwith JB, et al. Treatment outcomes in patients less than 2 years of age with small, stage I, favorable-histology Wilms' tumors: a report from the National Wilms' Tumor Study. J Clin Oncol 1993; 11:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/10\">",
"      Green DM, Breslow NE, Beckwith JB, et al. Effect of duration of treatment on treatment outcome and cost of treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 1998; 16:3744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/11\">",
"      Blute ML, Kelalis PP, Offord KP, et al. Bilateral Wilms tumor. J Urol 1987; 138:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/12\">",
"      Montgomery BT, Kelalis PP, Blute ML, et al. Extended followup of bilateral Wilms tumor: results of the National Wilms Tumor Study. J Urol 1991; 146:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/13\">",
"      Breslow NE, Palmer NF, Hill LR, et al. Wilms' tumor: prognostic factors for patients without metastases at diagnosis: results of the National Wilms' Tumor Study. Cancer 1978; 41:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/14\">",
"      Breslow N, Sharples K, Beckwith JB, et al. Prognostic factors in nonmetastatic, favorable histology Wilms' tumor. Results of the Third National Wilms' Tumor Study. Cancer 1991; 68:2345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/15\">",
"      Arrigo S, Beckwith JB, Sharples K, et al. Better survival after combined modality care for adults with Wilms' tumor. A report from the National Wilms' Tumor Study. Cancer 1990; 66:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/16\">",
"      Reinhard H, Aliani S, Ruebe C, et al. Wilms' tumor in adults: results of the Society of Pediatric Oncology (SIOP) 93-01/Society for Pediatric Oncology and Hematology (GPOH) Study. J Clin Oncol 2004; 22:4500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/17\">",
"      Grundy PE, Telzerow PE, Breslow N, et al. Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome. Cancer Res 1994; 54:2331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/18\">",
"      Perlman EJ, Grundy PE, Anderson JR, et al. WT1 mutation and 11P15 loss of heterozygosity predict relapse in very low-risk wilms tumors treated with surgery alone: a children's oncology group study. J Clin Oncol 2011; 29:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/19\">",
"      Grundy PE, Breslow NE, Li S, et al. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol 2005; 23:7312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/20\">",
"      D'Angio GJ. Pre- or postoperative therapy for Wilms' tumor? J Clin Oncol 2008; 26:4055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/21\">",
"      Messahel B, Williams R, Ridolfi A, et al. Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1-3 clinical trials: a Children's Cancer and Leukaemia Group (CCLG) Study. Eur J Cancer 2009; 45:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/22\">",
"      Spreafico F, Gamba B, Mariani L, et al. Loss of heterozygosity analysis at different chromosome regions in Wilms tumor confirms 1p allelic loss as a marker of worse prognosis: a study from the Italian Association of Pediatric Hematology and Oncology. J Urol 2013; 189:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/23\">",
"      Sredni ST, Gadd S, Huang CC, et al. Subsets of very low risk Wilms tumor show distinctive gene expression, histologic, and clinical features. Clin Cancer Res 2009; 15:6800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/24\">",
"      Williams RD, Al-Saadi R, Chagtai T, et al. Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor. Clin Cancer Res 2010; 16:2036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/25\">",
"      Huang CC, Gadd S, Breslow N, et al. Predicting relapse in favorable histology Wilms tumor using gene expression analysis: a report from the Renal Tumor Committee of the Children's Oncology Group. Clin Cancer Res 2009; 15:1770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/26\">",
"      Farber S. Chemotherapy in the treatment of leukemia and Wilms' tumor. JAMA 1966; 198:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/27\">",
"      D'Angio GJ, Evans AE, Breslow N, et al. The treatment of Wilms' tumor: Results of the national Wilms' tumor study. Cancer 1976; 38:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/28\">",
"      D'Angio GJ, Breslow N, Beckwith JB, et al. Treatment of Wilms' tumor. Results of the Third National Wilms' Tumor Study. Cancer 1989; 64:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/29\">",
"      Green DM, Breslow NE, Beckwith JB, et al. Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 1998; 16:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/30\">",
"      Shamberger RC, Guthrie KA, Ritchey ML, et al. Surgery-related factors and local recurrence of Wilms tumor in National Wilms Tumor Study 4. Ann Surg 1999; 229:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/31\">",
"      Green DM, Breslow NE, Beckwith JB, et al. Treatment with nephrectomy only for small, stage I/favorable histology Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 2001; 19:3719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/32\">",
"      Frazier AL, Shamberger RC, Henderson TO, Diller L. Decision analysis to compare treatment strategies for Stage I/favorable histology Wilms tumor. Pediatr Blood Cancer 2010; 54:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/33\">",
"      Shamberger RC, Anderson JR, Breslow NE, et al. Long-term outcomes for infants with very low risk Wilms tumor treated with surgery alone in National Wilms Tumor Study-5. Ann Surg 2010; 251:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/34\">",
"      B&uuml;rger D, Moorman-Voestermans CG, Mildenberger H, et al. The advantages of preoperative therapy in Wilms' tumour. A summarised report on clinical trials conducted by the International Society of Paediatric Oncology (SIOP). Z Kinderchir 1985; 40:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/35\">",
"      Lemerle J, Voute PA, Tournade MF, et al. Preoperative versus postoperative radiotherapy, single versus multiple courses of actinomycin D, in the treatment of Wilms' tumor. Preliminary results of a controlled clinical trial conducted by the International Society of Paediatric Oncology (S.I.O.P.). Cancer 1976; 38:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/36\">",
"      Lemerle J, Voute PA, Tournade MF, et al. Effectiveness of preoperative chemotherapy in Wilms' tumor: results of an International Society of Paediatric Oncology (SIOP) clinical trial. J Clin Oncol 1983; 1:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/37\">",
"      Tournade MF, Com-Nougu&eacute; C, Vo&ucirc;te PA, et al. Results of the Sixth International Society of Pediatric Oncology Wilms' Tumor Trial and Study: a risk-adapted therapeutic approach in Wilms' tumor. J Clin Oncol 1993; 11:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/38\">",
"      Tournade MF, Com-Nougu&eacute; C, de Kraker J, et al. Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms' tumor in children older than 6 months: results of the Ninth International Society of Pediatric Oncology Wilms' Tumor Trial and Study. J Clin Oncol 2001; 19:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/39\">",
"      Hall G, Grant R, Weitzman S, et al. Predictors of surgical outcome in Wilms' tumor: a single-institution comparative experience. J Pediatr Surg 2006; 41:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/40\">",
"      Fuchs J, Kienecker K, Furtw&auml;ngler R, et al. Surgical aspects in the treatment of patients with unilateral wilms tumor: a report from the SIOP 93-01/German Society of Pediatric Oncology and Hematology. Ann Surg 2009; 249:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/41\">",
"      D'Angio GJ. Pre- or post-operative treatment for Wilms tumor? Who, what, when, where, how, why--and which. Med Pediatr Oncol 2003; 41:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/42\">",
"      Mitchell C, Pritchard-Jones K, Shannon R, et al. Immediate nephrectomy versus preoperative chemotherapy in the management of non-metastatic Wilms' tumour: results of a randomised trial (UKW3) by the UK Children's Cancer Study Group. Eur J Cancer 2006; 42:2554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/43\">",
"      Ritchey ML, Green DM, Thomas PR, et al. Renal failure in Wilms' tumor patients: a report from the National Wilms' Tumor Study Group. Med Pediatr Oncol 1996; 26:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/44\">",
"      Ritchey ML, Coppes MJ. The management of synchronous bilateral Wilms tumor. Hematol Oncol Clin North Am 1995; 9:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/45\">",
"      Horwitz JR, Ritchey ML, Moksness J, et al. Renal salvage procedures in patients with synchronous bilateral Wilms' tumors: a report from the National Wilms' Tumor Study Group. J Pediatr Surg 1996; 31:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/46\">",
"      Hamilton TE, Ritchey ML, Haase GM, et al. The management of synchronous bilateral Wilms tumor: a report from the National Wilms Tumor Study Group. Ann Surg 2011; 253:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/47\">",
"      Davidoff AM, Giel DW, Jones DP, et al. The feasibility and outcome of nephron-sparing surgery for children with bilateral Wilms tumor. The St Jude Children's Research Hospital experience: 1999-2006. Cancer 2008; 112:2060.",
"     </a>",
"    </li>",
"    <li>",
"     Fernandez C, Geller JI, Ehrlich PF, et al. Renal tumors. In: Principles and Practice of Pediatric Oncology, 6th ed, Pizzo P, Poplack D (Eds), Lippincott Williams &amp; Wilkins, St. Louis 2011. p.861.",
"    </li>",
"    <li>",
"     Children's Oncology Group study AREN0534: Treatment for Patients with Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor. Chair: Peter Ehrlich. 2009-present.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/50\">",
"      Green DM, Beckwith JB, Breslow NE, et al. Treatment of children with stages II to IV anaplastic Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 1994; 12:2126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/51\">",
"      Smets AM, van Tinteren H, Bergeron C, et al. The contribution of chest CT-scan at diagnosis in children with unilateral Wilms' tumour. Results of the SIOP 2001 study. Eur J Cancer 2012; 48:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/52\">",
"      Grundy PE, Green DM, Dirks AC, et al. Clinical significance of pulmonary nodules detected by CT and Not CXR in patients treated for favorable histology Wilms tumor on national Wilms tumor studies-4 and -5: a report from the Children's Oncology Group. Pediatr Blood Cancer 2012; 59:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/53\">",
"      de Kraker J, Lemerle J, Vo&ucirc;te PA, et al. Wilm's tumor with pulmonary metastases at diagnosis: the significance of primary chemotherapy. International Society of Pediatric Oncology Nephroblastoma Trial and Study Committee. J Clin Oncol 1990; 8:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/54\">",
"      Pritchard J, Imeson J, Barnes J, et al. Results of the United Kingdom Children's Cancer Study Group first Wilms' Tumor Study. J Clin Oncol 1995; 13:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/55\">",
"      Nicolin G, Taylor R, Baughan C, et al. Outcome after pulmonary radiotherapy in Wilms' tumor patients with pulmonary metastases at diagnosis: a UK Children's Cancer Study Group, Wilms' Tumour Working Group Study. Int J Radiat Oncol Biol Phys 2008; 70:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/56\">",
"      Cotton CA, Peterson S, Norkool PA, et al. Early and late mortality after diagnosis of wilms tumor. J Clin Oncol 2009; 27:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/57\">",
"      Breslow NE, Ou SS, Beckwith JB, et al. Doxorubicin for favorable histology, Stage II-III Wilms tumor: results from the National Wilms Tumor Studies. Cancer 2004; 101:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/58\">",
"      Weirich A, Ludwig R, Graf N, et al. Survival in nephroblastoma treated according to the trial and study SIOP-9/GPOH with respect to relapse and morbidity. Ann Oncol 2004; 15:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/59\">",
"      Hamilton TE, Green DM, Perlman EJ, et al. Bilateral Wilms' tumor with anaplasia: lessons from the National Wilms' Tumor Study. J Pediatr Surg 2006; 41:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/60\">",
"      Coppes MJ, Arnold M, Beckwith JB, et al. Factors affecting the risk of contralateral Wilms tumor development: a report from the National Wilms Tumor Study Group. Cancer 1999; 85:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/61\">",
"      Abu-Ghosh AM, Krailo MD, Goldman SC, et al. Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms' tumor: a Children's Cancer Group report. Ann Oncol 2002; 13:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/62\">",
"      Dome JS, Liu T, Krasin M, et al. Improved survival for patients with recurrent Wilms tumor: the experience at St. Jude Children's Research Hospital. J Pediatr Hematol Oncol 2002; 24:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/63\">",
"      Grundy P, Breslow N, Green DM, et al. Prognostic factors for children with recurrent Wilms' tumor: results from the Second and Third National Wilms' Tumor Study. J Clin Oncol 1989; 7:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/64\">",
"      Dome JS, Bockhold CA, Li SM, et al. High telomerase RNA expression level is an adverse prognostic factor for favorable-histology Wilms' tumor. J Clin Oncol 2005; 23:9138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/65\">",
"      de Camargo B, Melaragno R, Saba e Silva N, et al. Phase II study of carboplatin as a single drug for relapsed Wilms' tumor: experience of the Brazilian Wilms' Tumor Study Group. Med Pediatr Oncol 1994; 22:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/66\">",
"      Ettinger LJ, Gaynon PS, Krailo MD, et al. A phase II study of carboplatin in children with recurrent or progressive solid tumors. A report from the Childrens Cancer Group. Cancer 1994; 73:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/67\">",
"      Kung FH, Desai SJ, Dickerman JD, et al. Ifosfamide/carboplatin/etoposide (ICE) for recurrent malignant solid tumors of childhood: a Pediatric Oncology Group Phase I/II study. J Pediatr Hematol Oncol 1995; 17:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/68\">",
"      Loss JF, Santos PP, Leone LD, Brunetto AL. Outcome of pediatric recurrent and refractory malignant solid tumors following ifosfamide/carboplatin/etoposide (ICE): A phase II study in a pediatric oncology centre in Brazil. Pediatr Blood Cancer 2004; 42:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/69\">",
"      Pein F, Pinkerton R, Tournade MF, et al. Etoposide in relapsed or refractory Wilms' tumor: a phase II study by the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group. J Clin Oncol 1993; 11:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/70\">",
"      Pein F, Tournade MF, Zucker JM, et al. Etoposide and carboplatin: a highly effective combination in relapsed or refractory Wilms' tumor--a phase II study by the French Society of Pediatric Oncology. J Clin Oncol 1994; 12:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/71\">",
"      Pinkerton CR, Pritchard J. A phase II study of ifosfamide in paediatric solid tumours. Cancer Chemother Pharmacol 1989; 24 Suppl 1:S13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/72\">",
"      Pratt CB, Horowitz ME, Meyer WH, et al. Phase II trial of ifosfamide in children with malignant solid tumors. Cancer Treat Rep 1987; 71:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/73\">",
"      Pratt CB, Douglass EC, Etcubanas E, et al. Clinical studies of ifosfamide/mesna at St Jude Children's Research Hospital, 1983-1988. Semin Oncol 1989; 16:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/74\">",
"      Saylors RL 3rd, Stewart CF, Zamboni WC, et al. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study. J Clin Oncol 1998; 16:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/75\">",
"      Schwartzman E, Scopinaro M, Angueyra N. Phase II study of ifosfamide as a single drug for relapsed paediatric patients. Cancer Chemother Pharmacol 1989; 24 Suppl 1:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/76\">",
"      Tournade MF. A phase II study of ifosfamide in the treatment of relapses in Wilms' tumor. Cancer Chemother Pharmacol 1989; 24 Suppl 1:S31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/77\">",
"      Ritchey ML, Shamberger RC, Haase G, et al. Surgical complications after primary nephrectomy for Wilms' tumor: report from the National Wilms' Tumor Study Group. J Am Coll Surg 2001; 192:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/78\">",
"      Termuhlen AM, Tersak JM, Liu Q, et al. Twenty-five year follow-up of childhood Wilms tumor: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer 2011; 57:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/79\">",
"      van Dijk IW, Oldenburger F, Cardous-Ubbink MC, et al. Evaluation of late adverse events in long-term wilms' tumor survivors. Int J Radiat Oncol Biol Phys 2010; 78:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/80\">",
"      Lange J, Peterson SM, Takashima JR, et al. Risk factors for end stage renal disease in non-WT1-syndromic Wilms tumor. J Urol 2011; 186:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/81\">",
"      Smith GR, Thomas PR, Ritchey M, Norkool P. Long-term renal function in patients with irradiated bilateral Wilms tumor. National Wilms' Tumor Study Group. Am J Clin Oncol 1998; 21:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/82\">",
"      Breslow NE, Norris R, Norkool PA, et al. Characteristics and outcomes of children with the Wilms tumor-Aniridia syndrome: a report from the National Wilms Tumor Study Group. J Clin Oncol 2003; 21:4579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/83\">",
"      Breslow NE, Collins AJ, Ritchey ML, et al. End stage renal disease in patients with Wilms tumor: results from the National Wilms Tumor Study Group and the United States Renal Data System. J Urol 2005; 174:1972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/84\">",
"      Grigoriev Y, Lange J, Peterson SM, et al. Treatments and outcomes for end-stage renal disease following Wilms tumor. Pediatr Nephrol 2012; 27:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/85\">",
"      Green DM, Grigoriev YA, Nan B, et al. Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study group. J Clin Oncol 2001; 19:1926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/86\">",
"      Sorensen K, Levitt G, Sebag-Montefiore D, et al. Cardiac function in Wilms' tumor survivors. J Clin Oncol 1995; 13:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/87\">",
"      Tefft M, Mitus A, Das L, et al. Irradiation of the liver in children: review of experience in the acute and chronic phases, and in the intact normal and partially resected. Am J Roentgenol Radium Ther Nucl Med 1970; 108:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/88\">",
"      Green DM, Norkool P, Breslow NE, et al. Severe hepatic toxicity after treatment with vincristine and dactinomycin using single-dose or divided-dose schedules: a report from the National Wilms' Tumor Study. J Clin Oncol 1990; 8:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/89\">",
"      Green DM, Peabody EM, Nan B, et al. Pregnancy outcome after treatment for Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol 2002; 20:2506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/90\">",
"      Kalapurakal JA, Peterson S, Peabody EM, et al. Pregnancy outcomes after abdominal irradiation that included or excluded the pelvis in childhood Wilms tumor survivors: a report from the National Wilms Tumor Study. Int J Radiat Oncol Biol Phys 2004; 58:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/91\">",
"      Byrne J, Mulvihill JJ, Connelly RR, et al. Reproductive problems and birth defects in survivors of Wilms' tumor and their relatives. Med Pediatr Oncol 1988; 16:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/92\">",
"      Breslow NE, Takashima JR, Whitton JA, et al. Second malignant neoplasms following treatment for Wilm's tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 1995; 13:1851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/93\">",
"      Breslow NE, Lange JM, Friedman DL, et al. Secondary malignant neoplasms after Wilms tumor: an international collaborative study. Int J Cancer 2010; 127:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/94\">",
"      Paulino AC, Wen BC, Brown CK, et al. Late effects in children treated with radiation therapy for Wilms' tumor. Int J Radiat Oncol Biol Phys 2000; 46:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/95\">",
"      Hogeboom CJ, Grosser SC, Guthrie KA, et al. Stature loss following treatment for Wilms tumor. Med Pediatr Oncol 2001; 36:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/50/9002/abstract/96\">",
"      Warwick AB, Kalapurakal JA, Ou SS, et al. Portal hypertension in children with Wilms' tumor: a report from the National Wilms' Tumor Study Group. Int J Radiat Oncol Biol Phys 2010; 77:210.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6237 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-EE7AE732F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_50_9002=[""].join("\n");
var outline_f8_50_9002=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROGNOSTIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Tumor histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Tumor stage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Biologic markers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Unilateral renal involvement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - National Wilms Tumor Study",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - International Society of Pediatric Oncology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Comparison of approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Bilateral renal involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Anaplastic histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Lung metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110256064\">",
"      Survival rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Tumor recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Early complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Late effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Screening for tumor recurrence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23821332\">",
"      - Pulmonary surveillance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23821339\">",
"      - Abdominal surveillance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Screening for therapy-related complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      FUTURE DIRECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6237\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6237|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/4/14413\" title=\"table 1\">",
"      Wilms tumor staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/54/25452\" title=\"table 2\">",
"      Wilms tumor rx regimen",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/12/2249?source=related_link\">",
"      Presentation, diagnosis, and staging of Wilms tumor",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_50_9003="Causes gestational hyperandrogenism";
var content_f8_50_9003=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F59214&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F59214&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of gestational hyperandrogenism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Luteoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Theca-lutein cysts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exogenous progestin or androgen administration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Placental aromatase deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sertoli-Leydig cell tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Miscellaneous ovarian tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Krukenberg tumors (gastrointestinal cancer metastatic to ovaries)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polycystic ovary syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adrenal tumors",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: McClamrock HD, Adashi EY. Gestational hyperandrogenism. In: Reproductive Endocrinology, Surgery, and Technology, Adashi EY, Rock JA, Rosenwaks Z (Eds), Lippincott-Raven, Philadelphia, 1996, p. 612.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_50_9003=[""].join("\n");
var outline_f8_50_9003=null;
var title_f8_50_9004="Myopathy and biochemical defect";
var content_f8_50_9004=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F59733&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F59733&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Correlation of metabolic myopathy symptoms and signs with specific biochemical defects",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Static symptoms and signs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acid maltase deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Branching enzyme deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Debranching enzyme deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carnitine transport defect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        LCAD, VLCAD deficiencies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trifunctional enzyme deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mitochondrial disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Dynamic symptoms and signs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phosphoylase b kinase deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myophosphorylase (PPL) deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phosphofructokinase (PFK) deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phosphoglycerate kinase (PGK) deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lactate dehydrogenase (LDH) deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carnitine palmitoyltransferase II (CPT II) deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fatty acid oxidation/mitochondrial defects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Static and dynamic symptoms and signs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myophosphorylase deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PFK, PPL b kinase deficiencies (plus fixed weakness)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Debranching enzyme deficiency (plus dynamic symptoms)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        LCAD, VLCAD, SCHAD deficiencies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trifunctional enzyme deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple mitochondrial DNA deletions",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     LCAD: long-chain acyl-CoA dehydrogenase; VLCAD: very long-chain acyl-CoA dehydrogenase; SCHAD: short-chain 3-hydroxyacyl-CoA dehydrogenase.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_50_9004=[""].join("\n");
var outline_f8_50_9004=null;
var title_f8_50_9005="Antiemetic drugs children";
var content_f8_50_9005=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60807&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60807&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected antiemetic therapies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug class/name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Receptor antagonist",
"       </td>",
"       <td class=\"subtitle1\">",
"        Indication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Antihistamine",
"       </td>",
"       <td rowspan=\"5\">",
"        Histamine",
"       </td>",
"       <td rowspan=\"5\">",
"        Motion sickness, chemotherapy",
"       </td>",
"       <td rowspan=\"5\">",
"        Sedation is a side effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cyclizine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dimenhydrinate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diphenhydramine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hydroxyzine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Anticholinergic",
"       </td>",
"       <td rowspan=\"2\">",
"        Acetylcholine",
"       </td>",
"       <td rowspan=\"2\">",
"        Motion sickness prophylaxis, used with opioids to treat post-operative nausea and vomiting",
"       </td>",
"       <td rowspan=\"2\">",
"        Dry mouth is a side effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hyoscyamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Benzodiazepine",
"       </td>",
"       <td rowspan=\"4\">",
"        GABA",
"       </td>",
"       <td rowspan=\"4\">",
"        Chemotherapy, cyclic vomiting",
"       </td>",
"       <td rowspan=\"4\">",
"        Rapid onset, short duration of action; sedation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lorazepam",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diazepam",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Midazolam",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Phenothiazine",
"       </td>",
"       <td rowspan=\"5\">",
"        Dopamine D2 receptor at the chemoreceptor trigger zone (CTZ)",
"       </td>",
"       <td rowspan=\"5\">",
"        Vomiting",
"       </td>",
"       <td rowspan=\"5\">",
"        Extrapyramidal side effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prochlorperazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chlorpromazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Perphenazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Promethazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Butyrophenones",
"       </td>",
"       <td rowspan=\"2\">",
"        Dopamine D2 receptor at the chemoreceptor trigger zone (CTZ)",
"       </td>",
"       <td rowspan=\"2\">",
"        Intractable emesis from gastritis",
"       </td>",
"       <td rowspan=\"2\">",
"        Drowsiness, sedation are side effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Droperidol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Benzamide",
"       </td>",
"       <td rowspan=\"2\">",
"        Dopamine D2 receptor at the chemoreceptor trigger zone (CTZ)",
"       </td>",
"       <td rowspan=\"2\">",
"        Gastroesophageal reflux, motility disorders",
"       </td>",
"       <td rowspan=\"2\">",
"        Potential risk of tardive dyskinesia associated with chronic or high-dose use.&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Metoclopramide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Anti-serotonin",
"       </td>",
"       <td rowspan=\"3\">",
"        Serotonin (5HT3)",
"       </td>",
"       <td rowspan=\"3\">",
"        Chemotherapy, post-op vomiting",
"       </td>",
"       <td rowspan=\"3\">",
"        Headache, constipation, and abdominal pain are reported side effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Odansetron",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Granisetron",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Macrolide",
"       </td>",
"       <td rowspan=\"2\">",
"        Motilin agonist",
"       </td>",
"       <td rowspan=\"2\">",
"        Gastroparesis and other motility disorders",
"       </td>",
"       <td rowspan=\"2\">",
"        Diarrhea and nausea are possible side effects. May alter metabolism of other drugs through inhibition of cytochrome P450.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Erythromycin",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     GABA: gamma aminobutyric acid.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_50_9005=[""].join("\n");
var outline_f8_50_9005=null;
var title_f8_50_9006="TEN prognosis by SCORTEN";
var content_f8_50_9006=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F58211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F58211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 478px\">",
"   <div class=\"ttl\">",
"    TEN prognosis by SCORTEN",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 458px; height: 296px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier Analysis of survival of patients with TEN based upon SCORTEN score, calculated within 24 hours of hospital admission.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Auegan, S, Bastuji-Aarin, S, Poszepczynska-Guigne, E, et al. J Invest Dermatol 2006, 126:272.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_50_9006=[""].join("\n");
var outline_f8_50_9006=null;
var title_f8_50_9007="Construction of a double barrel loop colostomy - colotomy";
var content_f8_50_9007=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F59093&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F59093&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Construction of a double barrel loop colostomy - colotomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 312px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure shows a colotomy being made on the antimesenteric surface of the colon with electrocautery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_50_9007=[""].join("\n");
var outline_f8_50_9007=null;
